United States



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.WASHINGTON, DC 20549

Form


FORM 10-Q

 


(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 201730, 2020

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________from ____ to ______________

 

Commission file numberFile Number: 000000-55181

 


TWINLAB CONSOLIDATED HOLDINGS, INC.Twinlab Consolidated Holdings, Inc.


(Exact name of registrantregistrant as specified in its charter)

 


Nevada

46-395174246-3951742

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

4800 T-Rex Avenue, Suite 305

Boca Raton, Florida

33431

(Address of principal executive offices)

33431

(Zip Code)

 

(561) 443-5301443-4301


(Registrant’sRegistrant’s telephone number, including area code)

 


Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 


Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

TLCC

OTC.PK

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer,filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

  

Non-accelerated filer ☐ (Do not check if a smaller reporting company)

Smaller reporting company

  

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of shares of common stock, $0.001 par value $0.001, outstanding on November 14, 201716, 2020 was 252,924,027258,058,131 shares.




Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “contemplate,” “anticipate,” “goals,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about our plans and ability to raise additional capital, including through equity offerings, debt financings, or other arrangements, and the potential impact of the COVID-19 pandemic on our business operations.

These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. You should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q and in “Part I, Item 1A — Risk Factors” included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on May 29, 2020 that could cause actual future results or events to differ materially from the forward-looking statements that we make.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

 


 

Twinlab Consolidated Holdings, Inc.

Form 10-Q

 

TABLE OF CONTENTS

Page No.

Part I - FINANCIAL INFORMATION

Item 1.

Financial Statements

Condensed Consolidated Balance Sheets (Unaudited)

1

Condensed Consolidated Statements of Operations (Unaudited)

2

Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited)

3

Condensed Consolidated Statements of Cash Flows (Unaudited)

4

Notes to Condensed Consolidated Financial Statements (Unaudited)

5

Item 2.

’Management's Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

27

Item 4.

Controls and Procedures

27

Part II - OTHER INFORMATION

Item 1.

Legal Proceedings

29

Item 1A.

Risk Factors

29

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

        29

 
    

Item 1.

Financial Statements 3.

1Defaults Upon Senior Securities

Condensed Consolidated Balance Sheets (Unaudited)2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)3
Condensed Consolidated Statements of Cash Flows (Unaudited)5
Notes to Condensed Consolidated Financial Statements (Unaudited)

29

 

 

 

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations4.

22Mine Safety Disclosures

      

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

27

Item 4.

Controls and Procedures

27

Part II - OTHER INFORMATION29

 
    

Item 1.

Legal Proceedings5.

29

Item1A.

Risk FactorsOther Information

29

    

Item 6.

Exhibits

Exhibits29

Signatures

30

Signatures

31

 


 

PART I I. – FINANCIAL INFORMATION

 

Item 1.      Financial Statements.

TWINLAB CONSOLIDATED HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(AMOUNTS IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)

  

September 30,

  

December 31,

 
  

2017

  

2016

 

ASSETS

        
         

Current assets:

        

Cash

 $2,233  $5,097 

Accounts receivable, net of allowance of $2,777 and $2,365, respectively

  8,737   7,768 

Inventories, net

  18,368   17,601 

Prepaid expenses and other current assets

  2,238   2,870 

Total current assets

  31,576   33,336 
         

Property and equipment, net

  3,240   3,528 

Intangible assets, net

  28,450   30,197 

Goodwill

  24,098   24,098 

Other assets

  1,768   1,667 
         

Total assets

 $89,132  $92,826 
         

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

        
         

Current liabilities:

        

Accounts payable

 $4,607  $7,866 

Accrued expenses and other current liabilities

  10,266   11,434 

Derivative liabilities

  8,143   6,455 

Notes payable and current portion of long-term debt, net of discount of $1,871 and $2,297, respectively

  17,091   11,631 

Total current liabilities

  40,107   37,386 
         

Long-term liabilities:

        

Deferred gain on sale of assets

  1,606   1,727 

Deferred tax liability

  959   959 

Notes payable and long-term debt, net of current portion and discount of $2,102 and $3,451, respectively

  57,162   50,988 

Total long-term liabilities

  59,727   53,674 
         

Total liabilities

  99,834   91,060 
         

Commitments and contingencies

        
         

Stockholders’ equity (deficit):

        

Preferred stock, $0.001 par value, 500,000,000 shares authorized, no shares issued and outstanding

  -   - 

Common stock, $0.001 par value, 5,000,000,000 shares authorized, 387,730,078 shares issued

  388   388 

Additional paid-in capital

  226,766   226,380 

Stock subscriptions receivable

  (30)  (30)

Treasury stock, 134,806,051 and 134,163,685 shares at cost, respectively

  (500)  (500)

Accumulated deficit

  (237,326)  (224,472)

Total stockholders’ equity (deficit)

  (10,702)  1,766 
         

Total liabilities and stockholders' equity (deficit)

 $89,132  $92,826 

 

Twinlab Consolidated Holdings, Inc.

Condensed Consolidated Balance Sheets (unaudited)

(amounts in thousands, except share and per share data)

  

September 30,

2020

  

December 31,

2019

 

ASSETS

        
         

Current assets:

        

Cash

 $877  $270 

Accounts receivable, net

  5,654   6,342 

Inventories, net

  8,234   6,569 

Prepaid expenses and other current assets

  3,627   3,119 

Total current assets

  18,392   16,300 
         

Property and equipment, net

  64   72 

Right-of-use assets

  4,916   - 

Intangible assets, net

  3,531   4,363 

Goodwill

  8,818   8,818 

Other assets

  778   834 
         

Total assets

 $36,499  $30,387 
         

LIABILITIES AND STOCKHOLDERS’ DEFICIT

        
         

Current liabilities:

        

Accounts payable

 $2,870  $6,313 

Lease liabilities

  696   - 

Accrued expenses and other current liabilities

  8,674   6,777 

Accrued interest

  18,648   13,895 

Derivative liabilities

  -   35 

Notes payable and current portion of long-term debt, net

  96,142   91,127 

Total current liabilities

  127,030   118,147 
         
         

Long-term liabilities:

        

Lease liabilities

  4,851   - 

Notes payable and long-term debt, net of current

  756   - 

Total long-term liabilities

  5,607   - 
         

Total liabilities

  132,637   118,147 
         

Stockholders’ deficit:

        

Preferred stock, $0.001 par value, 500,000,000 shares authorized, no shares issued and outstanding

  -   - 

Common stock, $0.001 par value, 5,000,000,000 shares authorized, 392,864,182 and 390,449,879 shares issued, respectively

  393   390 

Additional paid-in capital

  231,250   231,253 

Stock subscriptions receivable

  (30)  (30)

Treasury stock, 134,806,051 shares at cost

  (500)  (500)

Accumulated deficit

  (327,251)  (318,873)

Total stockholders’ deficit

  (96,138)  (87,760)
         

Total liabilities and stockholders' deficit

 $36,499  $30,387 

The accompanying notes are an integral part of thethese condensed consolidated financial statements.statements.

 


1

 

TWINLAB CONSOLIDATED HOLDINGS, INC.

Twinlab Consolidated Holdings, Inc.

Condensed Consolidated Statements of Operations (unaudited)

(amounts in thousands, except share and per share data)

CONDENSED CONSOLIDATED STATEMENTS OF

COMPREHENSIVE LOSS (UNAUDITED)

(AMOUNTS IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)

 

  

Three Months Ended

  

Nine Months Ended

 
  

September 30,

  

September 30,

 
  

2017

  

2016

  

2017

  

2016

 
                 

Net sales

 $20,612  $23,046  $66,130  $65,885 

Cost of sales

  17,103   15,963   50,368   49,405 
                 

Gross profit

  3,509   7,083   15,762   16,480 
                 

Selling, general and administrative expenses

  6,646   7,760   20,574   26,249 
                 

Loss from operations

  (3,137)  (677)  (4,812)  (9,769)
                 

Other income (expense):

                

Interest expense, net

  (1,876)  (2,423)  (6,318)  (6,530)

Loss on stock purchase guarantee

  -   -   -   (3,210)

Gain (loss) on change in derivative liabilities

  (393)  14,065   (1,688)  28,128 

Other income (expense), net

  (12)  3   (36)  (18)
                 

Total other income (expense)

  (2,281)  11,645   (8,042)  18,370 
                 

Income (loss) before income taxes

  (5,418)  10,968   (12,854)  8,601 

Provision for income taxes

  -   -   -   (17)
                 

Total comprehensive income (loss)

 $(5,418) $10,968  $(12,854) $8,584 
                 

Weighted average number of common shares outstanding – basic

  252,924,027   250,806,152   252,935,792   264,740,245 
                 

Net income (loss) per common share – basic

 $(0.02) $0.04  $(0.05) $0.03 
                 

Weighted average number of common shares outstanding – diluted (2016 corrected - see Note 1)

  252,924,027   264,224,781   252,935,792   277,221,732 
                 

Net loss per common share – diluted (2016 corrected - see Note 1)

 $(0.02) $(0.01) $(0.05) $(0.07)
  

Three Months Ended
September 30,

  

Nine Months Ended
September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Net sales

 $18,371  $19,851  $47,012  $57,558 

Cost of sales

  14,669   18,188   35,322   48,227 
                 

Gross profit

  3,702   1,663   11,690   9,331 
                 

Operating costs and expenses:

                

Selling expenses

  420   1,300   1,044   1,412 

General and administrative expenses

  2,981   4,198   12,567   16,933 
                 

Income (loss) from operations

  301   (3,835)  (1,921)  (9,014)
                 

Other income (expense):

                

Interest expense, net

  (2,183)  (2,154)  (6,489)  (7,580)

Gain on change in derivative liabilities

  178   2,789   35   474 

Other (expense)

  (148)  (16)  (3)  (36)

Loss on disposition of property and equipment

  -   -   -   (386)
                 

Total other income (expense)

  (2,153)  619   (6,457)  (7,528)
                 

Loss before income taxes

  (1,852)  (3,216)  (8,378)  (16,542)
                 

Provision for income taxes

  -   -   -   - 
                 

Total net loss

 $(1,852) $(3,216) $(8,378) $(16,542)
                 

Weighted average number of common shares outstanding - basic

  258,058,131   255,643,828   257,345,636   255,643,828 

Net loss per common share - basic

 $(0.01) $(0.01) $(0.03) $(0.06)
                 

Weighted average number of common shares outstanding - diluted

  259,086,721   266,746,810   260,486,654   266,746,810 

Net loss per common share - diluted (See Note 2)

 $(0.01) $(0.02) $(0.03) $(0.06)

 

The accompanying notes are an integra l part of these condensed consolidated financial statements.

2

Twinlab Consolidated Holdings, Inc.

Condensed Consolidated Statements of Stockholders’ Deficit (unaudited)

(amounts in thousands, except share and per share data)

  

Common Stock

  

Additional Paid-in

  

Stock Subscriptions

  

Treasury Stock

  

Accumulated

     
  

Shares

  

Amount

  Capital  Receivable  

Shares

  

Amount

  

Deficit

  

Total

 
                                 

Balance, December 31, 2018

  390,449,879  $390  $230,625  $(30)  134,806,051  $(500) $(274,372) $(43,887)

Reclassification of derivative liabilities

  -   -   628   -   -   -   -   628 

Net loss

  -   -   -   -   -   -   (8,784)  (8,784)

Balance, March 31, 2019

  390,449,879  $390  $231,253  $(30)  134,806,051  $(500) $(283,156) $(52,043)

Net loss

  -   -   -   -   -   -   (4,542)  (4,542)

Balance, June 30, 2019

  390,449,879  $390  $231,253  $(30)  134,806,051  $(500) $(287,698) $(56,585)

Net loss

  -   -   -   -   -   -   (3,216)  (3,216)

Balance, September 30, 2019

  390,449,879  $390  $231,253  $(30)  134,806,051  $(500) $(290,914) $(59,801)
                                 

Balance, December 31, 2019

  390,449,879  $390  $231,253  $(30)  134,806,051  $(500) $(318,873) $(87,760)

Shares issued upon exercise of warrants

  1,141,405   2   (2)  -   -   -   -   - 

Net loss

  -   -   -   -   -   -   (5,164)  (5,164)

Balance, March 31, 2020

  391,591,284  $392  $231,251  $(30)  134,806,051  $(500) $(324,037) $(92,924)

Shares issued upon exercise of warrants

  1,272,898   1   (1)  -   -   -   -   - 

Net loss

  -   -   -   -   -   -   (1,362)  (1,362)

Balance, June 30, 2020

  392,864,182  $393  $231,250  $(30)  134,806,051  $(500) $(325,399) $(94,286)

Net loss

  -   -   -   -   -   -   (1,852)  (1,852)

Balance, September 30, 2020

  392,864,182  $393  $231,250  $(30)  134,806,051  $(500) $(327,251) $(96,138)

The accompanying notes are an integral part of thethese condensed consolidated financial statements.

 


3

 

TWINLAB CONSOLIDATED HOLDINGS, INC.

Twinlab Consolidated Holdings, Inc.

Condensed Consolidated Statements of Cash Flows(unaudited)

(amounts in thousands)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(AMOUNTS IN THOUSANDS)

 

 

Nine Months Ended

 
 

September 30,

  

Nine Months Ended
September 30,

 
 

2017

  

2016

  

2020

  

2019

 

Cash flows from operating activities:

                

Net income (loss)

 $(12,854) $8,584 

Adjustments to reconcile net income (loss) to net cash used in operating activities:

        

Net loss

 $(8,378) $(16,542)

Adjustments to reconcile net loss to net cash used in operating activities

        

Depreciation and amortization

  2,416   2,212   860   1,330 

Amortization of right-to-use assets

  591   - 

Amortization of debt discount

  1,774   2,717   736   1,962 

Stock-based compensation

  386   540 

Provision for obsolete inventory

  466   1,194 

Provision for losses on accounts receivable

  167   267 

Loss on stock purchase price guarantee

  -   3,210 

(Gain) loss on change in derivative liabilities

  1,688   (28,128)

Recovery for provision for obsolete inventories

  (206)  (83)

Provision (recovery) for losses on accounts receivable

  (3,251)  2,700 

Gain on change in derivative liability

  (35)  (474)

Loss on disposal of property and equipment

  -   386 

Other non-cash items

  (121)  (124)  -   (122)

Changes in operating assets and liabilities:

                

Accounts receivable

  (1,136)  (2,293)

Accounts receivable, net

  3,939   (2,245)

Inventories

  (1,233)  (4,044)  (1,459)  779 

Prepaid expenses and other current assets

  632   (1,113)  (508)  1,391 

Other assets

  (101)  63   56   (194)

Accounts payable

  (3,259)  (5,241)  (3,443)  255 

Lease liabilities

  (599)  - 

Accrued expenses and other current liabilities

  2,032   1,621   7,289   3,135 
                

Net cash used in operating activities

  (9,143)  (20,535)  (4,408)  (7,722)
                

Cash flows from investing activities:

                

Purchase of property and equipment

  (51)  (119)  (20)  (20)
                

Cash flows from financing activities:

                

Proceeds from the exercise of warrants

  -   1 

Proceeds from the issuance of debt

  6,267   22,089   6,674   - 

Repayment of debt

  (1,583)  (2,973)  (2,310)  (955)

Net borrowings from revolving credit facility

  1,646   3,342   671   4,555 
                

Net cash provided by financing activities

  6,330   22,459   5,035   3,600 
                

Net increase (decrease) in cash

  (2,864)  1,805   607   (4,142)

Cash at the beginning of the period

  5,097   1,240   270   6,227 
                

Cash at the end of the period

 $2,233  $3,045  $877  $2,085 
        

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

        

Cash paid for interest

 $1,032  $938 
        

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

     

Reclassification of derivative liabilities

 $-  $628 

 

The accompanying notes are an integral part of thethese condensed consolidated financial statements.

 


4

TWINLAB CONSOLIDATED HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(AMOUNTS IN THOUSANDS) - Continued

  

Nine Months Ended

 
  

September 30,

 
  

2017

  

2016

 
         

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

        

Cash paid for interest

 $982  $3,818 

Cash paid for income taxes

  -   27 
         

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING TRANSACTIONS:

        

Decrease in derivative liabilities and increase in common stock and additional paid-in capital on exercise of warrants

 $-  $1,975 

Issuance of other liability for purchase of treasury shares

  -   500 

Relief of stock subscription accrual through long-term debt

  (3,200)  - 

Issuance of new long-term debt as payment of existing stock subscription accrual

  3,200   - 

Property and equipment acquired through the issuance of capital leases

  330   - 

Repayment of short-term debt

  -   (2,589)

Issuance of long-term debt

  -   2,589 

The accompanying notes are an integral part of the condensed consolidated financial statements.



 

TWINLAB CONSOLIDATED HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(AMOUNTS IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)

Twinlab Consolidated Holdings, Inc.

NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESNotes to Condensed Consolidated Financial Statements (unaudited)

(amounts in thousands, except share and per share amounts)

 

Note 1 – Nature of Business

Organization

Nature of Business

Twinlab Consolidated Holdings, Inc. (the “Company”, “Twinlab,” “we,” “our” and “us”) was incorporated on October 24, 2013 under the laws of the State of Nevada as Mirror Me, Inc. On August 7, 2014, we amended our articles of incorporation and changed our name to Twinlab Consolidated Holdings, Inc.

 

Nature of Operations

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores, mass market retailers, specialty stores retailers, on-line retailers and websites. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.

 

Our products include vitamins, minerals, specialty supplements and sports nutrition products sold under the Twinlab®Twinlab brand name (including the Twinlab® Fuel brand ofand REAAL sports nutrition products); a market leader in the healthy aging and beauty from within categories sold under the Reserveage™Reserveage Nutrition and ResVitale® brand names; diet and energy products sold under the Metabolife®Metabolife brand name; the Re-Body®Re-Body brand name; and a full line of herbal teas sold under the Alvita®Alvita brand name. To accommodate consumer preferences, our products come in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, sprays and powders. These products are sold primarily through health and natural food stores and on-line retailers, supermarkets, and mass-market retailers.

 

We also perform contract manufacturing services for private label products. Our contract manufacturing services business involves the manufacture of custom products to the specifications of a customer who requires finished product under the customer’s own brand name.  We do not market these private label products as our business is to manufacture and sell the products to the customer, who then markets and sells the products to retailers or end consumers.

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. As of September 30, 2020, we had an accumulated deficit of $327,251. Historical losses are primarily attributable to lower than planned sales resulting from low fill rates on demand due to limitations of our working capital, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with our debt refinancing. Losses have been funded primarily through debt.

Because of our history of operating losses and significant interest expense on our debt, we have a working capital deficiency of $108,638 as of September 30, 2020. We also have $96,142 of debt, net of discount, presented in current liabilities. These continuing conditions, among others, raise substantial doubt about our ability to continue as a going concern.

Management has addressed operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; reducing operating costs that include significant workforce and salary expense reduction and continuing to negotiate lower prices from major suppliers.  We believe that we may need additional capital to execute our business plan. If additional funding is required, there can be no assurance that sources of funding will be available when needed on acceptable terms or at all. To meet capital requirements, the Company may consider selling certain assets or seeking financing through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing agreements.

5

Note 2 – Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Except as described herein, there have been no changes in the Company’s significant accounting policies as described in Note 1, Nature of Operations and Summary of Significant Accounting Policies, within the “Notes to Consolidated Financial Statements” accompanying the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission (“SEC”) on May 29, 2020. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the periods presented. All amounts and disclosures set forth in this Quarterly Report on Form 10-Q reflect adoption of these changes.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Basis of Presentation and Unaudited Information

The condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with United States generally accepted accounting principles, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures are adequate to make the information presented not misleading. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management, are necessary for fair presentation of the information contained herein. Financial results for any interim period are not necessarily indicative of financial results that may be expected for the fiscal year. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 31, 2017.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principlesGAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant management estimates include those with respect to returns and allowances, allowance for doubtful accounts, reserves for inventory obsolescence, the recoverability of long-lived assets, intangibles and goodwill and the estimated value of warrants and derivative liabilities.

 

Contract Liabilities

Our contract liabilities consist of customer deposits and contractual guaranteed returns. Net contract liabilities are recorded in accrued expenses and other current liabilities and consisted of the following:

  

September 30, 2020

  

December 31, 2019

 

Contract Liabilities - Customer Deposits

 $4,239  $2,071 

Contract Liabilities - Guaranteed Returns

  58   56 
  $4,297  $2,127 


6

Disaggregation of Revenue

Revenue is disaggregated from contracts with customers by goods or services as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors. See details in the tables below.

  

Three Months Ended September 30, 2020

  

Three Months Ended September 30, 2019

 

Product Sales

 $18,291  $19,761 

Fulfillment Services

  80   90 
  $18,371  $19,851 

  

Nine Months Ended
September 30, 2020

  

Nine Months Ended
September 30, 2019

 

Product Sales

 $46,817  $57,015 

Fulfillment Services

�� 195   543 
  $47,012  $57,558 

 

 

Revenue RecognitionFair Value of Financial Instruments

Revenue from product sales, net of estimated returns and allowances, is recognized when evidence of an arrangement is in place, related prices are fixed and determinable, contractual obligations have been satisfied, title and risk of loss have been transferred to the customer and collection of the resulting receivable is reasonably assured. Shipping terms are generally freight on board shipping point. We sell predominately in the North American and European markets, with international sales transacted in U.S. dollars.

Fair Value of Financial Instruments

We apply the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

Level 1 – inputs are quoted prices in active markets for identical assets that the reporting entity has the ability to access at the measurement date.

 

Level 2 – inputs are other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly.

 

Level 3 – inputs are unobservable inputs for the asset that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability.

 

The following table summarizes our financial instruments that are measured at fair value on a recurring basis as of September 30, 20172020 and December 31, 2016:2019:

 

September 30, 2017

 

Total

  

Level 1

  

Level 2

  

Level 3

 
                 

Derivative liabilities

 $8,143  $-  $-  $8,143 

December 31, 2016

 

Total

  

Level 1

  

Level 2

  

Level 3

 
                 

Derivative liabilities

 $6,455  $-  $-  $6,455 

  

Total

  

Level 1

  

Level 2

  

Level 3

 

September 30, 2020:

                

Derivative liabilities

 $-  $-  $-  $- 

December 31, 2019:

                

Derivative liabilities

 $35  $-  $-  $35 

 

Accounts Receivable and Allowances

We grant credit to customers and generally do not require collateral or other security. We perform credit evaluations of our customers and provide for expected claims related to promotional items;items, customer discounts;discounts, shipping shortages; damages;shortages, damages, and doubtful accounts based upon historical bad debt and claims experience. As of September 30, 2017,2020, total allowances amounted to $2,777,$2,633, of which $314$1,375 was related to doubtful accounts receivable. As of December 31, 2016,2019, total allowances amounted to $2,365,$5,884, of which $481$5,107 was related to doubtful accounts receivable.

 

Inventories

Inventories are stated at the lower of cost or net realizable value and are reduced by an estimated reserve for obsolete inventory.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation, including amounts amortized under capital leases, is calculated on the straight-line method over the estimated useful livesA significant customer of the Company, General Nutrition Corporation (“GNC”), declared bankruptcy on June 23, 2020.  The Company has reserved the full amount of $2,829 related assets, which are 7 to 10 years for machinery and equipment, 8 years for furniture and fixtures and 3 years for computers. Leasehold improvements are amortized over the shorteraccounts receivable due from GNC as of the useful life of the asset or the term of the lease.balance sheet date.

Normal repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the related cost and accumulated depreciation or amortization is removed from the accounts and any gain or loss is included in the results of operations.


Intangible Assets

Intangible assets consist primarily of trademarks and customer relationships, which are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 30 years. The valuation and classification of these assets and the assignment of amortizable lives involve significant judgment and the use of estimates.

We believe that our long-term growth strategy supports our fair value conclusions. For intangible assets, the recoverability of these amounts is dependent upon achievement of our projections and the execution of key initiatives related to revenue growth and improved profitability.

Goodwill

Goodwill is not subject to amortization, but is reviewed for impairment annually, or more frequently whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. An impairment charge would be recorded to the extent the carrying value of goodwill exceeds its estimated fair value. The testing of goodwill under established guidelines for impairment requires significant use of judgment and assumptions. Changes in forecasted operations and other assumptions could materially affect the estimated fair values. Changes in business conditions could potentially require adjustments to these asset valuations.

Impairment of Long-Lived Assets

Long-lived assets, including intangible assets subject to amortization, are reviewed for impairment when changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If the carrying amount of the asset exceeds the expected undiscounted cash flows of the asset, an impairment charge is recognized equal to the amount by which the carrying amount exceeds fair value. The testing of these intangibles under established guidelines for impairment requires significant use of judgment and assumptions. Changes in forecasted operations and other assumptions could materially affect the estimated fair values. Changes in business conditions could potentially require adjustments to these asset valuations.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets relating to the asset acquisition of Organic Holdings, LLC (“Organic Holdings”), a market leader in the healthy aging and beauty from within categories and owner of the award-winning Reserveage™ Nutrition brand, are determined to have an indefinite useful economic life and as such are not amortized. Indefinite-lived intangible assets are tested for impairment annually which consists of a comparison of the fair value of the asset with its carrying value. The total indefinite-lived intangible assets as of September 30, 2017 and December 31, 2016 was $5,900.

Value of Warrants Issued with Debt

We estimate the grant date value of certain warrants issued with debt, using an outside professional valuation firm, which uses the Monte Carlo option lattice model. We record the amounts as interest expense or debt discount, depending on the terms of the agreement. These estimates involve multiple inputs and assumptions, including the market price of the Company’s common stock, stock price volatility and other assumptions to project earnings before interest, taxes, depreciation and amortization (“EBITDA”) and other reset events. These inputs and assumptions are subject to management’s judgment and can vary materially from period to period.

Derivative Liabilities

We have recorded certain warrants as derivative liabilities at estimated fair value, as determined based on our use of an outside professional valuation firm, due to the variable terms of the warrant agreements. The value of the derivative liabilities is generally estimated using the Monte Carlo option lattice model with multiple inputs and assumptions, including the market price of the Company’s common stock, stock price volatility and other assumptions to project EBITDA and other reset events. These inputs and assumptions are subject to management’s judgment and can vary materially from period to period.

Deferred gain on sale of assets

We entered into a sale-leaseback arrangement relating to our office facilities in 2013. Under the terms of the arrangement, we sold an office building and surrounding land and then leased the property back under a 15-year operating lease. We recorded a deferred gain for the amount of the gain on the sale of the asset, to be recognized as a reduction of rent expense over the life of the lease. Accordingly, we recorded amortization of deferred gain as a reduction of rental expense of $40 and $41 for the three months ended September 30, 2017 and 2016, respectively. For the nine months ended September 30, 2017 and 2016, we recorded amortization of $121 and $122, respectively. As of September 30, 2017 and December 31, 2016, unamortized deferred gain on sale of assets was $1,606 and $1,727, respectively.


 

Net Loss per Common Share

Basic net income or loss per common share (Basic EPS)(“Basic EPS”) is computed by dividing net income or loss by the weighted average number of common shares outstanding. Diluted net income or loss per common share (Diluted EPS)(“Diluted EPS”) is computed by dividing net income or loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common shares then outstanding. Potential dilutive common share equivalents consist of total shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock using the treasury stock method and the average market price per share during the period.

The common shares used in the computation of our basic and diluted net loss per share are reconciled as follows:

 

  

Three Months Ended

 

Nine Months Ended

 
  

September 30,

 

September 30,

 
  

2017

  

2016

   

2017

  

2016

 
      

(as corrected)

       

(as corrected)

 

Numerator:

                 

Net income (loss)

 $(5,418) $10,968   $(12,854) $8,584 

Effect of dilutive securities on net income (loss):

                 

Common stock warrants

  -   (14,065)   -   (28,128)
                  

Total net loss for purpose of calculating diluted net loss per common share

 $(5,418) $(3,097)  $(12,854) $(19,544)
                  

Number of shares used in per common share calculations:

                 

Total shares for purposes of calculating basic net loss per common share

  252,924,027   250,806,152    252,935,792   264,740,245 

Weighted-average effect of dilutive securities:

                 

Common stock warrants

  -   13,418,629    -   12,481,487 
                  

Total shares for purpose of calculating diluted net loss per common share

  252,924,027   264,224,781    252,935,792   277,221,732 
                  

Net income (loss) per common share:

                 

Basic

 $(0.02) $0.04   $(0.05) $0.03 

Diluted

 $(0.02) $(0.01)  $(0.05) $(0.07)
7

 

Correction of 2016 Diluted Net Loss Per Share

The diluted net loss per share for the period ended September 30, 2016 has been corrected. In accordance with U.S. generally accepted accounting principles, whenWhen calculating diluted earnings or loss per share, if the effects are dilutive, companies are required to add back to net income or loss the effects of the change in derivative liabilities related to warrants. Additionally, if the effects of the change in derivative liabilities are added back to net income or loss, companies are required to include the warrants outstanding related to the derivative liability in the calculation of the weighted average dilutive shares.

For the period ended September 30, 2016, as originally reported, we did not add back the effects of the change in the derivative liability in computing dilutive income or loss per share. The dilutive loss per share for the three and nine months ended September 30, 2016 in the table above has been revised to correct this error.

 

The table below reflectscommon shares used in the computation of our basic and diluted net loss per share as originally reported and net loss per share are reconciled as corrected for the three and nine months ended September 30, 2016.follows: 

  

As originally reported

  

As corrected

 
         

Diluted net income (loss) per common share (three months)

 $0.04  $(0.01)

Diluted net income (loss) per common share (nine months)

 $0.03  $(0.07)

Weighted average shares oustanding - diluted (three months)

  258,565,687   264,224,781 

Weighted average shares oustanding - diluted (nine months)

  275,633,914   277,221,732 

 

 

  

Three Months Ended
September 30,

  

Nine Months Ended
September 30,

 
  

2020

  

2019

  

2020

  

2019

 

Numerator:

                

Net loss

 $(1,852) $(3,216) $(8,378) $(16,542)

Effect of dilutive securities on net loss: Common stock warrants

  (178)  (2,789)  (35)  (474)
                 

Total net loss for purpose of calculating diluted net loss per common share

 $(2,030) $(6,005) $(8,413) $(17,016)
                 

Number of shares used in per common share calculations:

                

Total shares for purpose of calculating basic net loss per common share

  258,058,131   255,643,828   257,345,636   255,643,828 

Weighted-average effect of dilutive securities: Common stock warrants

  1,028,590   11,102,982   3,141,018   11,102,982 
                 

Total shares for purpose of calculating diluted net loss per common share

  259,086,721   266,746,810   260,486,654   266,746,810 
                 

Net loss per common share:

                

Basic

 $(0.01) $(0.01) $(0.03) $(0.06)

Diluted

 $(0.01) $(0.02) $(0.03) $(0.06)

The errors were corrected as of December 31, 2016, but since the adjustments were not material to any of the quarters previously reported, the Form 10-Qs for those periods were not amended. Management has determined the effects to be neither quantitatively or qualitatively material to the financial statements included in any of the Form 10-Qs filed during 2016.


 

Significant Concentration of Credit Risk

Sales to our top three customers aggregatedaggregated to approximately 33%27% and 25%33% of total sales for the three months ended September 30, 20172020 and 2016,2019, respectively, and 27%24% and 26%34% of total sales for the nine months ended September 30, 20172020 and 2016, respectively.2019. Sales to one of those customers were approximately 13%15% and 11%13% of total sales for the three months ended September 30, 20172020 and 2016,2019, respectively, and 12%9% and 11%13% of total sales for the nine months ended September 30, 20172020 and 2016,2019, respectively. Accounts receivable from these customers were approximately 55%A single customer represents 5% and 29%4% of total accounts receivable as of September 30, 20172020 and December 31, 2016,2019, respectively, and this customer is a related party through a director who sits on both the Company’s board and that of the customer. A significant customer of the Company, General Nutrition Corporation (“GNC”), declared bankruptcy on June 23, 2020. GNC was 3% and 13% of revenue in the three months ended September 30, 2020 and 2019, respectively. The Company has reserved all amounts related to accounts receivable due from GNC as of the balance sheet date.

Leases

The Company accounts for leases in accordance with Accounting Standards Codification ("ASC") 842. The Company reviews all contracts and determines if the arrangement is or contains a lease, at inception. Operating leases are included in right-of-use (“ROU”) assets, current lease liabilities and long-term lease liabilities on the condensed consolidated balance sheets. The Company does not have any finance leases. 

8

Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease ROU asset also includes any upfront lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with a term of 12 months or less are not recorded on the balance sheet. The Company’s lease agreements do not contain any residual value guarantees.

 

Recent New and Recently Adopted Accounting Pronouncements

In May 2017, FASB amended its guidance regarding the scope of modification accounting for share-based compensation arrangements. The amendments provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. For public entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. We do not expect the new guidance to have a significant impact on our condensed consolidated financial statements or related disclosures.

 

In January 2017, FASBthe Financial Accounting Standards Board (“FASB”) issued ASUan Accounting Standard Update (“ASU”) No. 2017-04, “SimplifyingSimplifying the Test for Goodwill Impairment (Topic 350) which removes Step 2 of the goodwill impairment test that requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019. Early adoption is permitted after January 1, 2017. We doThe adoption of this guidance effective January 1, 2020 did not expect the new guidance to have a significant impact on our condensed consolidated financial statements or related disclosures.

 

In February 2016, the FASB issued ASU No.No. 2016-02, “LeasesLeases (Topic 842)”. The amendments, which requires lessees to record most leases on the balance sheet and recognize the expenses on the income statement in thisa manner similar to current practice. ASU revise the accounting related to2016-02 states that a lessee accounting. Under the new guidance, lessees will be required towould recognize a lease liability for the obligation to make lease payments and a right-of-useright-to-use asset for all leases with terms greater than 12 months affecting the pattern of expense recognition inright to use the income statement. Leases previously defined as operating leases will be defined as financing leases and capitalized ifunderlying asset for the termlease term. For public entities, the new standard is greater than one year. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and interim periods within that reporting period. For all other entities, this standard is effective for annual reporting periods beginning after December 15, 2019 and interim periods within annual periods beginning after December 15, 2020. The Company adopted the standard using the modified retrospective approach as of January 1, 2020, with the effective date as of the date of initial application. Consequently, results for the three months and nine months ended September 30, 2020 are presented under Topic 842. No prior period amounts were adjusted and continue to be appliedreported in accordance with previous lease guidance, ASC Topic 840, Leases. The Company elected the practical expedients available under the provisions of the new standard, including: not reassessing whether expired or existing contracts are or contain leases; not reassessing the classification of expired or existing leases; and not reassessing the initial direct cost for any existing leases. The Company also elected the practical expedient allowing the use of hindsight in determining the lease term and assessing impairment of right-of-use assets based on all facts and circumstances through the effective date of the new standard. Upon adoption, and prior to Q1 FY20 activity, the Company recognized cumulative operating lease liabilities of $6.1 million and operating right-of-use assets of $5.5 million. 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments- Credit losses (Topic 326): Measurement of Credit losses on Financial Instruments. ASU 2016-13 requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Our status as a smaller reporting company allows us to defer adoption until the annual period, including interim periods within the annual period, beginning January 1, 2023. Management is currently evaluating the requirements of this guidance and has not yet determined the impact of the adoption on the Company's financial position or results from operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 amends the guidance for revenue recognition to replace numerous, industry-specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016; however, in July 2015, the FASB agreed to delay the effective date by one year. The proposed deferral may permit early adoption but would not allow adoption any earlier than the original effective date of the standard. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. Our prior status as an emerging growth company allowed us to defer the adoption until the annual reporting period beginning January 1, 2019, and interim reporting periods within the annual reporting period beginning January 1, 2020.  These condensed consolidated interim financial statements include the adoption of ASU 2014-09.  Beginning in our interim reporting period for the three months ended March 31, 2020, the Company used the modified retrospective transition approach for leases existing at, or entered into after, the beginningmethod of the earliest comparative period presented in the financial statements. Earlyadoption. The adoption is permitted. We are performing an assessment of our leases and have begun preparations for implementation and retrospective application to the earliest reporting period. As a result, financing leases will be recorded as an asset and a corresponding liability at the present value of the total lease payments. The asset will be decremented over the life of the lease on a pro-rata basis resulting in lease expense while the liability will be decremented using the interest method (ie. principal and interest). As such, we expect the new guidance will materially impact the asset and liability balances of our consolidated financial statements and related disclosures at the time of adoption.

Although there are several other new accounting pronouncements issued or proposed by FASB, which we have adopted or will adopt, as applicable, we dothis ASU did not believe any of these accounting pronouncements has had or will have a material impact on our the Company’s financial statements as the impact of this ASU was limited to reclassifying sales return reserves and additional disclosures in the notes to condensed consolidated financial position or resultsstatements. Sales return reserves were reclassified as a current liability instead of operations.as a reduction of accounts receivable of $383 and $56 as of January 1, 2019 and December 31, 2019, respectively.

 

9

NOTE 2 Note 3GOING CONCERNInventories

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. In most periods since our formation, we have generated losses from operations. At September 30, 2017, we had an accumulated deficit of $237,326. Historical losses are primarily attributable to lower than planned sales resulting from low fill rates on demand due to limitations of our working capital, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with our debt refinancing. Losses have been funded primarily through issuance of common stock and third-party or related party debt.

Because of our history of operating losses, significant interest expense on our debt, and the recording of significant derivative liabilities, we have a working capital deficiency of $8,531 at September 30, 2017. We also have $17,091 of debt, net of discount, due within the next 12 months. These continuing conditions, among others, raise substantial doubt about our ability to continue as a going concern.


Management has addressed operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; reducing manufacturing and operating costs and continuing to negotiate lower prices from major suppliers. We believe that we may need additional capital to execute our business plan. If additional funding is required, there can be no assurance that sources of funding will be available when needed on acceptable terms or at all.

NOTE 3 – INVENTORIES

Inventories consisted of the following at:

  

September 30,

  

December 31,

 
  

2017

  

2016

 
         

Raw materials

 $6,348  $4,912 

Work in process

  2,013   1,189 

Finished goods

  12,411   13,438 
   20,772   19,539 

Reserve for obsolete inventory

  (2,404)  (1,938)
  $18,368  $17,601 

NOTE 4 – PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at:

  

September 30,

  

December 31,

 
  

2017

  

2016

 
         

Machinery and equipment

 $12,156  $10,885 

Computers and other

  9,500   9,119 

Aquifer

  482   482 

Leasehold improvements

  1,518   1,518 
   23,656   22,004 

Accumulated depreciation and amortization

  (20,416)  (18,476)
  $3,240  $3,528 

Assets held under capital leases are included in machinery and equipment and amounted to $1,082 and $1,142 as of September 30, 2017 and December 31, 2016, respectively.

Depreciation and amortization expense totaled $222 and $221 for the three months ended September 30, 2017 and 2016, respectively, and totaled $669 and $567 for the nine months ended September 30, 2017 and 2016, respectively.following:

 


  

September 30, 2020

  

December 31, 2019

 

Raw materials

 $1,277  $- 

Finished goods

  7,998   7,816 
   9,275   7,816 

Reserve for obsolete inventory

  (1,041)  (1,247)
         

Inventories, net

 $8,234  $6,569 

 

NOTE N5ote 4 INTANGIBLE ASSETSIntangible Assets

 

Intangible assets consisted of the following at:following:

 

  

September 30,

  

December 31,

 
  

2017

  

2016

 
         

Trademarks

 $12,166  $12,166 

Indefinite-lived intangible assets

  5,900   5,900 

Customer relationships

  19,110   19,110 

Other

  753   753 
   37,929   37,929 

Accumulated amortization

  (9,479)  (7,732)
  $28,450  $30,197 

  

September 30, 2020

  

December 31, 2019

 
         

Trademarks

 $3,459  $6,880 

Indefinite-lived intangible assets

  1,400   1,400 

Customer relationships

  8,663   8,663 

Other

  -   753 
   13,522   17,696 

Accumulated amortization

  (9,991)  (13,333)
         

Intangible assets, net

 $3,531  $4,363 

 

Trademarks are amortized over periodsperiods ranging from 3 to 30 years and customer relationships are amortized over periods ranging from 151 to 16 years, and other intangible assets are amortized over 3 years. Amortization expense was $582$277 and $557$379 for the three months ended September 30, 20172020, and 2016,2019, respectively, and was $1,747$832 and $1,645$1,137 for the nine months ended September 30, 20172020 and 2016,2019, respectively.

 


10

 

NOTE N6ote 5 DEBTDebt

 

Debt consisted of the following at:following: 

 

 

September 30,

  

December 31,

  

September 30,

  

December 31,

 
 

2017

  

2016

  

2020

  

2019

 
        

Related-Party Debt:

        

July 2014 note payable to Little Harbor, LLC, net of unamortized discount of $0 and $206 as of September 30, 2017 and December 31, 2016, respectively

 $3,267  $3,061 

Related Party Debt:

        

July 2014 note payable to Little Harbor, LLC

 $3,267  $3,267 

July 2016 note payable to Little Harbor, LLC

  4,770   4,770   4,770   4,770 

January 2016 note payable to Great Harbor Capital, LLC

  2,500   2,500   2,500   2,500 

March 2016 note payable to Great Harbor Capital, LLC

  7,000   7,000   7,000   7,000 

December 2016 note payable to Great Harbor Capital, LLC

  2,500   2,500   2,500   2,500 

August 2017 note payable to Great Harbor Capital, LLC

  3,000   -   3,000   3,000 

February 2018 note payable to Great Harbor Capital, LLC

  2,000   2,000 

July 2018 note payable to Great Harbor Capital, LLC, net of discount of $261 and $563 at September 30, 2020 and December 31, 2019, respectively

  4,739   4,437 

November 2018 note payable to Great Harbor Capital, LLC, net of discount of $317 and $354 at September 30, 2020 and December 31, 2019, respectively

  3,683   3,646 

February 2020 note payable to Great Harbor Capital, LLC

  2,500   - 

January 2016 note payable to Golisano Holdings LLC

  2,500   2,500   2,500   2,500 

March 2016 note payable to Golisano Holdings LLC

  7,000   7,000   7,000   7,000 

July 2016 note payable to Golisano Holdings LLC

  4,770   4,770   4,770   4,770 

December 2016 note payable to Golisano Holdings LLC

  2,500   2,500   2,500   2,500 

March 2017 note payable to Golisano Holdings LLC

  3,267   -   3,267   3,267 

November 2014 note payable to Golisano Holdings LLC (formerly payble to Penta

        

Mezzanine SBIC Fund I, L.P.), net of discount and unamortized loan fees in the aggregate of $1,694 and $2,304 as of September 30, 2017 and December 31, 2016, respectively

  6,306   5,696 

January 2015 note payable to Golisano Holdings LLC (formerly payable to JL-BBNC

        

Mezz Utah, LLC), net of discount and unamortized loan fees in the aggregate of $2,058 as of September 30, 2017

  2,942   - 

February 2015 note payable to Golisano Holdings LLC (formerly payable to Penta

        

Mezzanine SBIC Fund I, L.P.), net of discount and unamortized loan fees in the aggregate of $148 and $201 as of September 30, 2017 and December 31, 2016, respectively

  1,852   1,799 

Total related-party debt

  54,174   44,096 

February 2018 note payable to Golisano Holdings LLC

  2,000   2,000 

February 2020 note payable to Golisano Holdings LLC

  2,500   - 

November 2014 note payable to Golisano Holdings LLC (formerly payable to Penta Mezzanine SBIC Fund I, L.P.), net of discount and unamortized loan fees in the aggregate of $130 and $271 at September 30, 2020 and December 31, 2019, respectively

  7,870   7,729 

January 2015 note payable to Golisano Holdings LLC (formerly payable to JL-BBNC Mezz Utah, LLC), net of discount and unamortized loan fees in the aggregate of $214 and $457 at September 30, 2020 and December 31, 2019, respectively

  4,786   4,543 

February 2015 note payable to Golisano Holdings LLC (formerly payable to Penta Mezzanine SBIC Fund I, L.P.), net of discount and unamortized loan fees in the aggregate of $12 and $25 at September 30, 2020 and December 31, 2019, respectively

  1,988   1,975 

Macatawa Bank

  15,000   15,000 

Total related party debt

  90,140   84,404 
                

Senior Credit Facility with Midcap, net of unamortized loan fees of $73 and $293 as of September 30, 2017 and December 31, 2016, respectively

  14,901   13,035 

Senior Credit Facility with Midcap

  5,084   4,413 
                

Other Debt:

                

January 2015 note payable to JL-BBNC Mezz Utah, LLC, net of discount and unamortized loan fees in the aggregate of $2,744 as of December 31, 2016

  -   2,256 

April 2016 note payable to JL-Utah Sub, LLC

  396   500 

Capital lease obligations

  1,582   2,732 

Huntington Holdings

  3,200   - 

Huntington Holdings, LLC

  -   2,310 

May 2020 Note Payable to Fifth Third Bank, N.A.

  1,674   - 

Total other debt

  5,178   5,488   1,674   2,310 
                

Total debt

  74,253   62,619   96,898   91,127 

Less current portion

  (17,091)  (11,631)  96,142   91,127 
        

Long-term debt

 $57,162  $50,988  $756  $- 

 


11

 

Related-Party DebtLittle Harbor LLC

Mr. David L. Van Andel, the Chairman of the Company’s Board of Directors, is the owner and principal of Little Harbor LLC. Mr. Mark Bugge, at the time the notes were entered into, was a member of the Company’s Board of Directors and the Secretary of Little Harbor LLC. 

July 2014 Note Payable to Little Harbor, LLC

Pursuant to a July 2014 Debt Repayment Agreement with Little Harbor, LLC (“Little Harbor”), an entity owned by certain stockholders of the Company, on February 6, 2018 we are obligatedentered into an agreement with Little Harbor to pay such party $4,900 per year in structured monthly payments for 3 years provided that such payment obligations will terminateconvert a debt repayment obligation of $3,267 into an unsecured promissory note (“Little Harbor Debt Repayment Note”). The note bears interest at such earlier time asan annual rate of 8.5%, with the trailing ninety day volume weighted average closing sales price of the Company’s common stock on all domestic securities exchanges on which such stock is listed equals or exceeds $5.06 per share. This note is unsecured and maturedprincipal payable at maturity. The Little Harbor Debt Repayment Note was scheduled to mature on July 25, 20172020; however, Little Harbor and the Company amended this note remains outstanding and principal payment has been deferred to 2018. This note was non-interest bearing, accordingly, using an imputed interest rate of 16.2%, we recorded a note discount in July 2014, which has been amortized into interest expense based onextend the effective interest rate method over the term of the note.maturity to October 22, 2021.

 

July 2016 Note Payable to Little Harbor, LLC

On

In July 21, 2016, we issued an Unsecured Delayed Draw Promissory Noteunsecured delayed draw promissory note in favor of Little Harbor (“Little Harbor Delayed Draw Note”), pursuant to which Little Harbor may, in its sole discretion and pursuant to draw requests made byloaned us the Company, loan us up to the maximum principalfull approved amount of $4,770. This note is unsecured and matures on January 28, 2019.$4,770 during the year ended December 31, 2016. This note bears interest at an annual rate of 8.5%, with the principal payable at maturity. If Little Harbor, in its discretion, accepts a draw request made by the Company under this note, Little Harbor shall not transfer cash to the Company, but rather Little Harbor shall irrevocably agree to accept the principal amount of any monthly delayed draw under this note in lieu and in complete satisfaction of the obligation to make an equivalent dollar amount of periodic cash payments otherwise due to Little Harbor under the July 2014 note payable. During the year ended December 31, 2016, we requested and Little Harbor LLC approved, draws totaling $4,770. We issued a warrant into escrow in connection with this loan (see Little Harbor Escrow WarrantsWarrant in Note 7)6). This note is unsecured and was scheduled to mature on January 28, 2019; however, in January 2019, the Company and Little Harbor amended this note to extend the maturity to June 30, 2019; then in July 2019, the Company and Little Harbor amended the note to extend the maturity to October 22, 2021.

Little Harbor has delivered a deferment letter pursuant to which Little Harbor agreed to defer all payments due under the aforementioned notes held by Little Harbor, through March 31, 2021 and agreed to refrain from declaring a default and/or exercising any remedies under the notes. 

 

Great Harbor Capital LLC

Mr. David L. Van Andel, the Chairman of the Company’s Board of Directors, is the owner and principal of Great Harbor Capital LLC. Mr. Mark Bugge, at the time the notes were entered into, was a member of the Company’s Board of Directors and the Secretary of Great Harbor Capital LLC.

January 2016 Note Payable to Great Harbor Capital, LLC

Pursuant to a January 28, 2016 Unsecured Promissory Noteunsecured promissory note (“January 2016 GH Note”) with Great Harbor Capital, LLC (“GH”), an affiliate of a member of our Board of Directors, GH lent us $2,500. The note matures on January 28, 2019,2016 GH Note bears interest at an annual rate of 8.5%, with the principal payable in 24 monthly installments of $104 which payment was to commence on February 28, 2017 but has beenwas deferred to January 28, 2018.August 31, 2019. We issued a warrant into escrow in connection with this loan (see GH Escrow Warrants in Note 7)6). The original maturity date of the January 2016 GH Note was January 28, 2019; however, on January 23, 2019, the Company and GH amended the January 2016 GH Note to extend the maturity to June 30, 2019, then in July, 2019, the Company and GH amended this note to extend the maturity to October 22, 2021.

March 2016 Note Payable to Great Harbor Capital, LLC

Pursuant to a March 21, 2016 Unsecured Promissory Note,unsecured promissory note (“March 2016 GH Note”), GH lent us $7,000. The note matures onThis March 21, 2019,2016 GH Note bears interest at an annual rate of 8.5%, with the principal payable in 24 monthly installments of $292 which payment was to commence on April 21, 2017 but has beenwas deferred to January 21, 2018.August 30, 2019. We issued a warrant into escrow in connection with this loan (see GH Escrow Warrants in Note 7)6). The note was scheduled to mature on March 21, 2019; however, in January 2019, the Company and GH amended this note to extend the maturity to June 30, 2019, then in July 2019, the Company and GH amended this note to extend the maturity to October 22, 2021.

 

December 2016 Note Payable to Great Harbor Capital, LLC

Pursuant to a December 31, 2016 Unsecured Promissory Note,unsecured promissory note (“December 2016 GH Note”), GH lent us $2,500. The note matures on December 30, 2019,2016 GH Note bears interest at an annual rate of 8.5%, with the principal payable at maturity. We issued a warrant into escrow in connection with this loan (see GH Escrow Warrants in Note 7)6). The note was scheduled to mature on December 31, 2019; however, in July 2019, the Company and GH amended this note to extend the maturity to October 22, 2021.

 

12

August 2017 Note Payable to Great Harbor Capital, LLC

Pursuant to an August 30, 2017 Secured Promissory Note,secured promissory note, GH lent us $3,000.$3,000 (“August 2017 GH Note”). The note matures on August 29, 2020,2017 GH Note bears interest at an annual rate of 8.5%, with the principal payable at maturity. We issued a warrant into escrow in connection with this loan (see GH Escrow Warrants in Note 7)6). The note was scheduled to mature on August 29, 2020; however, in July 2019, the Company and GH amended this note to extend the maturity to October 22, 2021.

 

February 2018 Note Payable to Great Harbor Capital, LLC

Pursuant to a February 6, 2018 secured promissory note, GH lent us $2,000 (“February 2018 GH Note”). The note bears interest at an annual rate of 8.5%, with the principal payable at maturity. This note is secured by collateral and is subordinate to the indebtedness owed to Midcap Funding X Trust as successor-by-assignment from MidCap Financial Trust (“MidCap”). The note was scheduled to mature on February 6, 2021; however, in July 2019, the Company and GH amended this note to extend the maturity to October 22, 2021.

As previously reported, on February 6, 2018, the Company issued an amended and restated secured promissory note to GH (“A&R August 2017 GH Note”) replacing the prior secured promissory note issued on August 30, 2017. The amendment and restatement added a requirement that when the Company consummates any Special Asset Disposition (as defined in the February 2018 GH Note), provided that the Company has a minimum liquidity of $1,000, the Company will use the net cash proceeds from the Special Asset Disposition to pay any accrued and unpaid interest under the A&R August 2017 GH Note and any other note subject to the Intercreditor Agreement (defined below). The interest rate and payment terms remain unchanged from the original secured promissory note issued to GH on August 30, 2017; however, the maturity date has been extended to October 22, 2021.

Furthermore, as a result of notes issued on February 6, 2018, by GH and Golisano Holdings LLC (“Golisano LLC”), GH and Golisano LLC entered into an “Intercreditor Agreement” where they agreed that each of the February 2018 GH Note, A&R August 2017 GH Note, and the Golisano LLC February 2018 Note are pari passu as to repayment, security and otherwise and are equally and ratably secured.

July 2018 Note Payable to Great Harbor Capital, LLC

Pursuant to a July 27, 2018 secured promissory note, GH loaned the Company $5,000 ("July 2018 GH Note"). The July 2018 GH Note bears interest at an annual rate of 8.5%, with the principal payable on maturity. Interest on the outstanding principal accrues at a rate of 8.5% per year and is payable monthly on the first day of each month, beginning September 1, 2018. The principal of the July 2018 GH Note was payable at maturity on January 27, 2020. The July 2018 GH Note is secured by collateral. We issued a warrant to GH in connection with this loan (see GH Warrants in Note 6). The note was scheduled to mature on January 27, 2020; however, in July 2019, the Company and GH amended this note to extend the maturity date to October 22, 2021.

The July 2018 GH Note is subordinate to the indebtedness owed to MidCap. The July 2018 GH Note is senior to the indebtedness owed to Little Harbor and Golisano Holdings LLC.

November 2018 Note Payable to Great Harbor Capital, LLC

Pursuant to a November 5, 2018 secured promissory note, GH loaned the Company $4,000 ("November 2018 GH Note"). The November 2018 GH Note bears interest at an annual rate of 8.5%, with the principal payable on maturity. Interest on the outstanding principal accrues at a rate of 8.5% per year and is payable monthly on the first day of each month, beginning December 1, 2018. The principal of the November 2018 GH Note is payable at maturity on November 5, 2020. The November 2018 GH Note is secured by collateral. We issued a warrant to GH in connection with this loan (see GH Warrants in Note 6). The November 2018 GH Note was scheduled to mature on November 5, 2020; however, in July 2019, the Company and GH amended this note to extend the maturity to October 22, 2021.

February 2020 Note Payable to Great Harbor Capital, LLC

Pursuant to a February 2020 unsecured promissory note (“February 2020 GH Note”), an affiliate of a member of our Board of Directors, GH lent us $2,500. The February 2020 GH Note bears interest at an annual rate of 8%, with the principal payable at the maturity of October 22, 2021.  

GH has delivered a deferment letter pursuant to which GH agreed to defer all payments due under the aforementioned notes held by GH, through October 22, 2021 and agreed to refrain from declaring a default and/or exercising any remedies under the notes. 

13

Golisano Holdings LLC

Mr. B. Thomas Golisano, a member of the Company’s Board of Directors is a principal of Golisano Holdings LLC. 

November 2014 Note Payable to Golisano Holdings LLC (formerly payable to Penta Mezzanine SBIC Fund I, L.P.)

On November 13, 2014, we raised proceeds of $8,000, less certain fees and expenses, from the issuance of a secured note to Penta Mezzanine SBIC Fund I, L.P. (“Penta”). The Managing Directormanaging director of Penta, an institutional investor, is also a director of our Company. We granted Penta a security interest in our assets and pledged the shares of our subsidiaries as security for the note. On March 8, 2017, Golisano Holdings, LLC (“Golisano LLC”) acquired this note payable from Penta.Penta (the “First Golisano Penta Note”). Interest on the outstanding principal accrued at a rate of 12% per year from the date of issuance to March 8, 2017, and decreased to 8% per year thereafter, payable monthly. The note matures on November 13, 2019. On August 30, 2017, we entered into an amendment withCompany and Golisano LLC which extended payment of principalamended this note to maturity.extend the maturity from November 5, 2020 to October 22, 2021. We issued a warrant to Penta to purchase 4,960,740 shares of the Company’s common stock in connection with this loan (see Golisano LLC Warrants formerly Penta Warrants in Note 7)6). The estimated fair value of the warrant at the date of issuance was $3,770, which was recorded as a note discount and is being amortized into interest expense over the term of this loan. Additionally, we had incurred loan fees of $273, which is also being amortized into interest expense over the term of this loan.

 


January 2015 Note Payable to Golisano Holdings LLC (formerly payable to JL-Mezz Utah, LLC-f/k/a JL-BBNC Mezz Utah, LLC)

On January 22, 2015, we raised proceeds of $5,000, less certain fees and expenses, from the sale of a note to JL-Mezz Utah, LLC (f/k/a JL-BBNC Mezz Utah, LLC) (“JL-US”). The proceeds were restricted to pay a portion of the Nutricap Labs, LLC (“Nutricap”) asset acquisition. We granted JLJL-US a security interest in the Company’s assets, including real estate and pledged the shares of our subsidiaries as security for the note. On March 8, 2017, Golisano LLC acquired this note payable from JL.

JL-US. Interest on the outstanding principal accrued at a rate of 12% per year from the date of issuance to March 8, 2017, and decreased to 8% per year thereafter, payable monthly.monthly (the “Golisano JL-US Note”). The note matures on November 13, 2019.October 22, 2021. On August 30, 2017, we entered into an amendment with Golisano LLC which extended payment of principal to maturity. We issued a warrant to JLJL-US to purchase 2,329,400 shares of the Company’s common stock on January 22, 2015 and 434,809 shares of the Company’s common stock on February 4, 2015 (see JL Warrants in Note 7)6).  The estimated fair value of these warrants at the date of issuances was $4,389, which was recorded as a note discount and is being amortized into interest expense over the term of these loans. Additionally, we had incurred loan fees of $152 relating to this loan, which is also being amortized into interest expense over the term of these loans.

 

February 2015 Note Payable to Golisano Holdings LLC (formerly payable to Penta Mezzanine SBIC Fund I, L.P.)

On February 6, 2015, we raised proceeds of $2,000, less certain fees and expenses, from the issuance of a secured note payable to Penta. The proceeds were restricted to pay a portion of the acquisition of the customer relationshipsrelationships of Nutricap. On March 8, 2017, Golisano LLC acquired this note payable from Penta.Penta (the “Second Golisano Penta Note”). Interest on the outstanding principal accrued at a rate of 12% per year from the date of issuance to March 8, 2017, and decreased to 8% per year thereafter, payable monthly. The note matures on November 13, 2019.October 22, 2021. On August 30, 2017, we entered into an amendment with Golisano LLC which extended payment of principal to maturity. We issued a warrant to Penta to purchase 869,618 shares of the Company’s common stock in connection with this loan (see Golisano LLC Warrants formerly Penta Warrants in Note 7)6). The estimated fair value of these warrants at the date of issuances totaled $250, which was recorded as a note discount and is being amortized into interest expense over the term of this loan. Additionally, we had incurred loan fees of $90, which is also being amortized into interest expense over the term of these loans.

 

January 2016 Note Payable to Golisano Holdings LLC

Pursuant to a January 28, 2016 Unsecured Promissory Noteunsecured promissory note with Golisano LLC (“Golisano LLC January 2016 Note”), an affiliate of a member of our Board of Directors, Golisano LLC lent us $2,500. The note matureswas scheduled to mature on January 28, 2019; however, on January 28, 2019, the Company and Golisano LLC entered into Amendment No. 1 to Amended and Restated Unsecured Promissory Note, which extended the maturity date of the note to June 30, 2019, then on July 8, 2019, the Company and Golisano LLC entered into Amendment No. 2 to Amended and Restated Unsecured Promissory Note, with an effective date of June 30, 2019, which extended the maturity date of the note from June 30, 2019 to October 22, 2021. This note bears interest at an annual rate of 8.5%, with the principal payable in 24 monthly installments of $104 which was to commence on February 28, 2017 but has been deferred to January 28, 2018.. We issued a warrant into escrow in connection with this loan (see Golisano Escrow Warrants in Note 7)6).

 

March 2016 Note Payable to Golisano Holdings LLC

Pursuant to a March 21, 2016 Unsecured Promissory Note,unsecured promissory note, Golisano LLC lent us $7,000.$7,000 (“Golisano LLC March 2016 Note”). The note matureswas scheduled to mature on March 21, 2019; however, on July 8, 2019, the Company and Golisano LLC entered into Amendment No. 1 to Amended and Restated Unsecured Promissory Note, which extended the maturity date of the note to June 30, 2019, then on July 8, 2019, the Company and Golisano LLC entered into Amendment No. 2 to Amended and Restated Unsecured Promissory Note, with an effective date of June 30, 2019, which extended the maturity date of the note from June 30, 2019 to October 22, 2021.This note bears interest at an annual rate of 8.5%, with the principal payable in 24 monthly installments of $292 which was to commence on April 21, 2017 but has been deferred to January 21, 2018.. We issued a warrant into escrow in connection with this loan (see Golisano Escrow Warrants in Note 7)6).

 

14

July 2016 Note Payable to Golisano Holdings LLC

On July 21, 2016, we issued an Unsecured Delayed Draw Promissory Noteunsecured delayed draw promissory note in favor of Golisano LLC pursuant to which Golisano LLC may, in its sole discretion and pursuant to draw requests made by the Company, loan the Company up to the maximum principal amount of $4,770 (the “Golisano LLC July 2016 Note”). TheDuring the year ended December 31, 2016, we requested and Golisano LLC approved, draws totaling $4,770.The Golisano LLC July 2016 Note matureswas scheduled to mature on January 28, 2019.2019; however, in July 2019, the Company and Golisano LLC amended this note to extend the maturity date to October 22, 2021. Interest on the outstanding principal accrues at a rate of 8.5% per year. The principal of the Golisano LLC July 2016 Note is payable at maturity. We issued a warrant into escrow in connection with this loan (see Golisano Escrow Warrants in Note 7)6). During the year ended December 31, 2016, we requested and Golisano LLC approved, draws totaling $4,770.

 

December 2016 Note Payable to Golisano Holdings LLC

Pursuant to a December 31, 2016 Unsecured Promissory Note,unsecured promissory note, as amended and restated, Golisano LLC lent us $2,500.$2,500 (“Golisano LLC December 2016 Note”). The note matures on December 30, 2019, bears interest at an annual rate of 8.5%, with the principal payable at maturity. We issued a warrant into escrow in connection with this loan (see Golisano Escrow Warrants in Note 7)6). The note was scheduled to mature on December 30, 2019; however, in July 2019, the Company and Golisano LLC amended this note to extend the maturity date to October 22, 2021.

 


March 2017 2017 Note Payable to Golisano Holdings LLC

Pursuant to a March 14, 2017 Unsecured Promissory Note,unsecured promissory note, as amended and restated, Golisano LLC lent us $3,267.$3,267 (“Golisano LLC March 2017 Note”). The note matures on December 30, 2019, bears interest at an annual rate of 8.5%, with the principal payable at maturity. We issued a warrant into escrow in connection with this loan (see Golisano Escrow Warrants in Note 7)6). The note was scheduled to mature on December 30, 2019; however, in July 2019, the Company and Golisano LLC amended this note to extend the maturity date to October 22, 2021.

February 2018 Note Payable to Golisano Holdings LLC

Pursuant to a February 6, 2018 secured promissory note, Golisano LLC lent us $2,000 (“Golisano LLC February 2018 Note”). The note bears interest at an annual rate of 8.5%, with the principal payable at maturity. This note is secured by collateral and is subordinate to the indebtedness owed to MidCap. The note was scheduled to mature on February 6, 2021; however, in July 2019, the Company and Golisano LLC amended this note to extend the maturity date to October 22, 2021.

February 2020 Note Payable to Golisano Holdings LLC

Pursuant to a February 2020 unsecured promissory note (“Golisano LLC February 2020 Note”), an affiliate of a member of our Board of Directors, Golisano LLC lent us $2,500. The Golisano LLC February 2020 Note bears interest at an annual rate of 8%, with the principal payable at the maturity date of October 22, 2021.   

Golisano LLC has delivered a deferment letter pursuant to which Golisano LLC agreed to defer all payments due under the aforementioned notes held by Golisano LLC through October 22, 2021 and agreed to refrain from declaring a default and/or exercising any remedies under the notes.  

Macatawa Bank

Mr. Mark Bugge is a former member of the board of directors of Macatawa Bank (“Macatawa”) and was a member of the Company’s board of directors; he was an active member of both boards at the time of the term loan note. Two other members of the Company’s Board of Directors, Mr. B. Thomas Golisano and Mr. David L. Van Andel, are the owners and principals of the guarantor, 463IP Partners, LLC (“463IP”). Furthermore, Mr. Van Andel, through his interest in a trust, holds an indirect limited partnership interest in White Bay Capital, LLLP, which has an ownership interest of greater than 10% in Macatawa.

On December 4, 2018, the Company entered into a Term Loan Note and Agreement (the "Term Loan") in favor of Macatawa. Pursuant to the Term Loan, Macatawa loaned the Company $15,000. The Term Loan matures on November 30, 2020. The Term Loan accrues interest at the interest rate equivalent to the one-month LIBOR Rate plus 1.00% (the interest rate will not be less than 2.50%; the rate was 2.50% as of September 30, 2020). After the maturity date or upon the occurrence or continuation of an event of default, the unpaid principal balance shall bear interest at the interest rate of the note plus 3.00%. The note is secured by the Limited Guaranty, defined below, and is subordinate to the indebtedness owed to MidCap.

15

In connection with the Term Loan, 463IP has entered into a limited guaranty, dated as of December 4, 2018, in favor of Macatawa (the "Limited Guaranty") pursuant to which it has agreed to guarantee payment under the Term Loan and any and all renewals of the Term Loan and all interest accrued on such indebtedness limited to $15,000 plus any accrued interest. 

Senior Credit Facility with Midcap

On January 22, 2015, we entered into a three-year $15,000 revolving credit facility (the “Senior Credit Facility”) pursuant to a credit and security agreement, based on our accounts receivable and inventory, increasablewhich could be increased to up to $20,000 upon satisfaction of certain conditions, with MidCap. MidCap Financial Trust, which subsequently assigned the agreement to an affiliate, Midcap Funding X Trust (“MidCap”). Trust.

On September 2, 2016, we entered into an amendment with Midcap to increase the Senior Credit Facility to $17,000 and extend our facility an additional 12 months. We granted MidCap a first priority security interest in certain of our assets and pledged the shares of our subsidiaries as security for amounts owed under the credit facility.Senior Credit Facility. We are required to pay Midcap an unused line fee of 0.50% per annum, a collateral management fee of 1.20% per month and interest of LIBOR plus 5% per annum, which was 6.24%5% per annum as of September 30, 2017.2020. We issued a warrant to Midcap to purchase 500,000 shares of the Company’s common stock (see Midcap Warrant in Note 7)6).

On January 22, 2019, we entered into Amendment Sixteen to the Credit and Security Agreement (the "MidCap Sixteenth Amendment"). The estimated fair valueMidCap Sixteenth Amendment reduced the revolving credit facility amount from a total of these warrants at$17,000 to a total of $5,000 and extended the expiration date from January 22, 2019 to April 22, 2019.

On February 13, 2019, MidCap informed the Company that MidCap had re-assigned all of issuance was $130,its rights, powers, privileges and duties as “Agent” under the Credit and Security Agreement, as well as all of its right, title and interest in and to the revolving loans made under the facility from Midcap Funding X Trust to MidCap IV Funding.

On April 22, 2019, we entered into Amendment Seventeen to the Credit and Security Agreement (the "MidCap Seventeenth Amendment"), which was recorded as a note discounteffectively increased the revolving credit facility amount to $12,000 and is being amortized into interest expense over the term ofrenewed the Senior Credit Facility. Additionally, weFacility for an additional two years expiring on April 22, 2021. 

We have incurred loan fees totaling $540 relating to the Senior Credit Facility and anythe subsequent amendments, which is also being amortized into interest expense over the term of the Senior Credit Facility.

Other Debt The balance owed on the Senior Credit Facility was $5,084 as of September 30, 2020.

 

April 2016 Note Payable to Other Debt JL-Utah Sub, LLC

Pursuant to an April 5, 2016 Unsecured Promissory Note, JL-Utah Sub, LLC lent us $500. The note matures on March 21, 2019, bears interest at an annual rate of 8.5%, with the principal payable in 24 monthly installments of $21 commencing on April 21, 2017.

Capital Lease Obligations

Our capital lease obligations pertain to various leasing agreements with Essex Capital Corporation (“Essex”), a related party to the Company as Essex’s principal owner is a director of the Company.

 

2014 Huntington Holdings,, LLC

On August 6, 2016, the 18-month anniversary of the closing of a share purchase agreement, we were required to pay the purchaser of the common stock the difference between $2.29 per share and either a defined market price or a price per share determined by a valuation firm acceptable to both parties. Based on an outside professional valuation performed on the Company’s common stock, the Company estimated the stock price guarantee payment to be $3,210. Accordingly, the Company recorded a loss on the stock purchase price guarantee of $3,210 and a corresponding liability for the same amount in 2016, which was included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of December 31, 2016. 

On June 2, 2017, the two parties came toCompany issued an agreement in which we were required to issue an Unsecured Promissory Note (“Huntingtonunsecured promissory note (the “Huntington Note”) in favor of 2014 Huntington Holdings LLC (“Huntington”). TheIn June 2019, the Company and Huntington amended the Huntington Note matures on June 2, 2019 with therelating to an original principal amount of $3,200 payable at maturity. Interest on$3,210 to extend the outstanding principal accruesmaturity date to September 3, 2019. The Company satisfied the note as of March 18, 2020.

May 2020 Note Payable to Fifth Third Bank N.A.

On May 7, 2020, Twinlab Consolidated Corporation ("TCC"), the operating subsidiary of the Company, received the proceeds of a loan from Fifth Third Bank, National Association in the amount of $1,674 obtained under the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted March 27, 2020 (the "PPP Loan”). The PPP Loan, evidenced by a promissory note dated May 5, 2020 (the “Note”), has a two-year term and bears interest at a rate of 8.5%1.0% per year from August 6, 2016annum, with expected monthly principal and interest payments due to August 15, 2017, and increases to 10% per year thereafter. We paid $50 to Huntington related to accrued interest from August 6, 2016 through the date of issuancebegin December 1, 2020. TCC may prepay 20% or less of the Huntington Note. Huntington was required to return 778,385 sharesprincipal balance of the Company’s common stock which were issued into escrow. We were requiredNote at any time without notice. TCC utilized and will continue to provide certain piggyback registration rights to Huntington in regards toutilized the remaining 749,999 sharesproceeds of the Company’s common stock held by Huntington. If the Huntington Note was paid off prior to August 14, 2017, the 778,385 shares held in escrow were to be released from escrowPPP Loan for payroll, office rent, and transferred toutilities which will allow the Company to seek forgiveness for no additional consideration. If the note remained outstanding on August 15, 2017, we had the right, but not the obligation, to pay $140 to Huntington to purchase 764,192 of the shares held in escrow (the “Subject Shares”). Upon the exercise of this purchase option, the Subject Shares were to be released from escrow and transferred to the Company. If the note remained outstanding on August 15, 2017 and we did not exercise the option to purchase the shares, the shares were to be returned from escrow to Huntington and we would no longer have repurchase rights. On August 15, 2017, the note was outstanding and we did not excerise the repurchase right. The 778,385 shares were returned from escrow to Huntington.loan.


16

 

Financial Covenants

 

Certain of the foregoing debt agreements,, as amended, require us to meet certain affirmative and negative covenants, including maintenance of specified ratios. We amended our debt agreements with MidCap, Penta and JL, effective July 29, 2016, to, among other things, reset the financial covenants of each debt agreement. As of September 30, 2017, management believes2020, we arewere in default for lack of compliance with ourthe EBITDA-related financial covenantscovenant of the debt agreement with MidCap. The amount due to MidCap for each debt agreement.this revolving credit line is $5,084 as of September 30, 2020.

 

NOTE 7 Note WARRANTS6 AND REGISTRATION RIGHTS AGREEMENTS– Warrants and Registration Rights Agreements

 

The following table presents a summary of the status of our issued warrants as of September 30, 2017,2020, and changes during the nine months then ended:

 

     

Weighted Average

  

Shares

Underlying

Warrants

  

Weighted

Average

xercise

Price

 
 

Shares

  

Exercise Price

         
        
        

Outstanding, December 31, 2016

  15,855,017   0.18 
        

Outstanding, December 31, 2019

  11,811,649  $0.14 

Granted

  -   -   -   - 

Canceled / Expired

  -   -   (4,397,346)  0.37 

Exercised

  -   -   (2,414,303)  0.00 

Outstanding, September 30, 2017

  15,855,017   0.18 
        

Outstanding, September 30, 2020

  5,000,000  $0.09 

 

Midcap Warrant

Warrants Issued

Midcap Warrant

In connection with theThe line of credit agreement with MidCap described in Note 6, we5 has been amended from time to time and when it was necessary under the terms of the agreement to obtain MidCap's consent to the transactions contemplated by the above mentioned GH notes and Golisano LLC notes. On April 22, 2019 subsequent to entering into the MidCap Seventeenth Amendment as noted in Note 5, the Company issued MidCap a warrant to MidCap exercisable through January 22, 2018, for an aggregate ofup to 500,000 shares of the Company’sCompany common stock at an exercise price of $0.76 per share (the “MidCap Warrant”"MidCap Warrant 3”). We entered into a Registration Rights Agreement with Midcap, dated as of January 22, 2015, granting MidCap certain registration rights, commencing October 1, 2015, for theThe Company has reserved 500,000 shares of Company common stock issuable on exercise offor issuance under the MidCap Warrant.Warrant 3. The MidCap Warrant 3, if exercisable, expires on April 22, 2021.

 

Penta Warrants

Pursuant to a stock purchase agreement dated June 30, 2015, a warrant was issued to Penta to purchase an aggregate 807,018 shares of our common stock at a price of $0.01 per share at any time prior to the close of business on June 30, 2020. We granted Penta certain registration rights, commencing October 1, 2015, for the shares of common stock issuable upon exercise of the warrant. The 807,018 warrants were exercised on June 23, 2020.

 

JL Warrants

Pursuant to a June 30, 2015 stock purchase agreement, a warrant was issued to JL (as defined below) to purchase an aggregate 403,509 shares of the Company’sCompany’s common stock at a price of $0.01 per share at any time prior to the close of business on June 30, 2020, subject to certain adjustments. We granted JL certain registration rights, commencing October 1, 2015, for the shares of common stock issuable upon exercise of the warrant. The warrant was subsequently assigned by JL to two individuals.

Essex Warrants

In connection with the guarantee of a note payable issued in the Nutricap asset acquisition and equipment financing by Essex discussed in Note 6, Essex was issued a warrant exercisable for an aggregate 1,428,571 shares of the Company’s common stock at a purchase price of $0.77 per share, at any time prior to the close of business The warrants expired unexercised on June 30, 2020. The number of shares issuable upon the exercise of the warrant is subject to adjustment on terms and conditions customary for a transaction of this nature in the event of (i) reorganization, recapitalization, stock split-up, combination of shares, mergers, consolidations and (ii) sale of all or substantially all of our assets or property. Essex subsequently assigned warrants for 350,649 shares to another company.

 

JL Properties, Inc. Warrants

In April 2015, we entered into an office lease agreement which requires a $1,000 security deposit, subject to reduction if we achieve certain market capitalization metrics at certain dates. On April 30, 2015, we entered into a reimbursement agreement with JL Properties, Inc. (“JL Properties”) pursuant to which JL Properties agreed to arrange for and provide an unconditional, irrevocable, transferable, and negotiable commercial letter of credit to serve as the security deposit. As partial consideration for the entry by JL Properties into the reimbursement agreement and the provision of the letter of credit, we issued JL Properties two warrants to purchase shares of the Company’sCompany’s common stock.

 


17

 

The first warrant iswas exercisable for an aggregate of 465,880 shares of common stock, subject to certain adjustments, at an aggregate purchase price of $0.01, at any time prior to April 30, 2020. In addition to adjustments on terms and conditions customary for a transaction of this nature in the event of (i) reorganization, recapitalization, stock split-up, combination of shares, mergers, consolidations and (ii) sale of all or substantially all of our assets or property, the number of shares of common stock issuable pursuant to the warrant will becould have been increased in the event our consolidated audited adjusted EBITDA (as defined in the warrant agreement) for the fiscal year endingended December 31, 2018 does2019 did not equal or exceed $19,250. JL Properties subsequently assigned the warrant to two individuals.

On December 31, 2019, our adjusted EBIDTA yielded a negative calculation; therefore, the warrant did not increase in number of shares of common stock.

 

The second warrant iswas exercisable for an aggregate of 86,962 shares of common stock, at a per share purchase price of $1.00, at any time prior to April 30, 2020. The number of shares issuable upon exercise of the second warrant iswas subject to adjustment on terms and conditions customary for a transaction of this nature in the event of (i) reorganization, recapitalization, stock split-up, combination of shares, mergers, consolidations and (ii) sale of all or substantially all of our assets or property.

 

We have granted JL Properties certain registration rights, commencing October 1, 2015, for the shares of common stock issuable on exercise of the two warrants. JL Properties has transferred these rights to two individuals.

 

On April 30, 2020 the Company extended the related letter of credit to April 30, 2021 for consideration of $25 to JL Properties.

The first 465,880 warrants (Warrant 2016-9 and Warrant 2016-10) were exercised on April 20, 2020 and the second 86,962 warrants (Warrant 2015-14) expired unexercised on April 30, 2020, both of which were issued in conjunction with the reimbursement agreement with JL Properties related to the commercial line of credit.

Golisano LLC Warrants (formerly Penta Warrants)

In connection with the November 13, 2014 note for $8,000 (see Note 6), Penta was issued a warrant to acquire 4,960,740 shares of the Company’s common stock at an aggregate exercise price of $0.01, through November 13, 2019. In connection with Penta’s consent to the terms of additional debt obtained by us, we also granted Penta a warrant to acquire an additional 869,618 shares of common stock at a purchase price of $1.00 per share, through November 13, 2019. Both warrant agreements grant Penta certain registration rights, commencing October 1, 2015, for the shares of common stock issuable on exercise of the warrants. Penta has the right, under certain circumstances, to require us to purchase all or any portion of the equity interest in the Company issued or represented by the warrant to acquire 4,960,740 shares at a price based on the greater of (i) the product of (x) ten times our adjusted EBITDA with respect to the twelve months preceding the exercise of the put right multiplied by (y) the investor’s percentage ownership in the Company assuming full exercise of the warrant; or (ii) the fair market value of the investor’s equity interest underlying the warrant. In the event (i) we do not have the funds available to repurchase the equity interest under the warrant or (ii) such repurchase is not lawful, adjustments to the principal of the note purchased by Penta will be made or, under certain circumstances, interest will be charged on the amount otherwise due for such repurchase. We have the right, under certain circumstances, to require Penta to sell to us all or any portion of the equity interest issued or represented by the warrant to acquire 4,960,740 shares. The price for such repurchase will be the greater of (i) the product of (x) eleven times our adjusted EBITDA with respect to the twelve months preceding the exercise of the call right multiplied by (y) the investor’s percentage ownership in the company assuming full exercise of the warrant; or (ii) the fair market value of the equity interests underlying the warrant; or (iii) $3,750. In connection with Golisano LLC’s acquisition of the note payable from Penta on March 8, 2017 (see Note 6 above for additional information), these warrants were assigned to Golisano LLC.JL Warrants)

 

Golisano LLC Warrants (formerly JL Warrants)

In connection with the January 22, 2015 note payable to JL,JL-US, we issued JLJL-US warrants to purchase an aggregate of 2,329,400 shares of the Company’s common stock, at an aggregate exercise price of $0.01, through February 13, 2020. On February 4, 2015, we also granted to JLJL-US a warrant to acquire a total of 434,809 shares of common stock at a purchase price of $1.00 per share, through February 13, 2020. Both warrant agreements grant JLJL-US certain registration rights, commencing October 1, 2015, for the shares of common stock issuable upon exercise of the warrants. These warrants were subsequently assigned to two individuals. During the year ended December 31, 2016, these individuals exercised warrants for a total of 1,187,995 shares of the Company’s common stock for total proceeds to the Company of less than $1.$1.00. In connection with Golisano LLC’s acquisition of the note payable from JLJL-US on March 8, 2017 (see Note 65 above for additional information), the remaining portions of these warrants were assigned to Golisano LLC. The remaining 1,141,405 warrants related to the January 22, 2015 agreement (Warrant 2015-5, Warrant 2015-6, Warrant 2015-7 and Warrant 2015-8) were exercised on January 20, 2020. The 434,809 warrants related to the February 4, 2015 agreement (Warrant 2015-10, Warrant 2015-11, Warrant 2015-20, Warrant 2015-21 and Warrant 2015-23) expired unexercised on February 13, 2020.

 


Golisano LLC Warrants

 

Golisano LLC Warrants

Pursuant to an October 2015 Securities Purchase Agreement with Golisano LLC, we issued Golisano LLC a warrant (the “Golisano Warrant”),which Golisano Warrant is intended to maintain, following each future issuance of shares of common stock pursuant to the conversion, exercise or exchange of certain currently outstanding warrants to purchase shares of common stock held by third-parties (the “Outstanding Warrants”), Golisano LLC’s proportional ownership of our issued and outstanding common stock so that it is the same thereafter as on October 5, 2015. We haveUpon issuance we had reserved 12,697,977 shares of common stock for issuance under the Golisano Warrant. The purchase price for any shares of common stock issuable upon exercise of the Golisano Warrant is $.001 per share. The Golisano Warrant is exercisable immediately and up to and including the date which is sixty days after the later to occur of the termination, expiration, conversion, exercise or exchange of all of the Outstanding Warrants and our delivery of notice thereof to Golisano LLC. The Golisano Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets. In addition, if any payments are made to a holder of an Outstanding Warrant in consideration for the termination of or agreement not to exercise such Outstanding Warrant, Golisano LLC will be entitled to equal treatment. We have entered into a registration rights agreement with Golisano LLC, dated as of October 5, 2015, granting Golisano LLC certain registration rights for the shares of common stock issuable on exercise of the Golisano Warrant. On February 6, 2016, Golisano LLC exercisedAs of September 30, 2020, all Outstanding Warrants had expired or been exercised. 

18

GH Warrants

In connection with the GolisanoJuly 2018 GH Note, we issued GH a warrant to purchase an aggregate of 2,500,000 shares of the Company’s common stock at an exercise price of $0.01 per share (the "July 2018 GH Warrant"). The July 2018 GH Warrant in part for 509,141is exercisable on any business day prior to the expiration date. The Company has reserved 2,500,000 shares of the Company’s common stock for issuance under the July 2018 GH Warrant. The July 2018 GH Warrant expires on July 27, 2024. The July 2018 GH Warrant is also subject to customary adjustments upon any recapitalization, reorganization, stock split, combination of shares, merger or consolidation. The Company estimated the value of the warrant using the Black-Scholes option pricing model and recorded a debt discount of $1,479, which will be amortized over the term of the July 2018 GH Note.

In connection with the November 2018 GH Note, we issued GH a warrant to purchase an aggregate purchaseof 2,000,000 shares of the Company’s common stock at an exercise price of $1. During the year ended December 31, 2016, the Golisano$0.01 per share (the "November 2018 GH Warrant"). The November 2018 GH Warrant was cancelled in part for 6,857,143 shares pursuantis exercisable on any business day prior to the cancellation of a portionexpiration date. The Company has reserved 2,000,000 shares of the Outstanding Warrants. As of September 30, 2017, we have reserved 4,756,505 shares of itsCompany’s common stock for issuance under the GolisanoNovember 2018 GH Warrant. The November 2018 GH Warrant expires on November 5, 2024. The November 2018 GH Warrant is also subject to customary adjustments upon any recapitalization, reorganization, stock split, combination of shares, merger or consolidation. The Company estimated the value of the warrant using the Black-Scholes option pricing model and recorded a debt discount of $1,214 which will be amortized over the term of the November 2018 GH Note.

Warrants Issued into Escrow

 

At September 30, 2020, there were 21,730,287 outstanding warrants held in escrow (“Escrow Warrants”). These Escrow Warrants are held in escrow and are not exercisable unless the Company defaults on the related debt. These Escrow Warrants are as follows:

Golisano Escrow Warrants

In connection with athe Golisano LLC January 28, 2016 Unsecured Promissory Note, we issued into escrow in the name of Golisano LLC a warrant to purchase an aggregate of 1,136,363 shares of the Company’s common stock at an exercise price of $0.01 per share (the “January 2016 Golisano Warrant”). The January 2016 Golisano Warrant will not be released from escrow or be exercisable unless and until we fail to pay Golisano LLC the entire unamortized principal amount of the related promissory note and any accrued and unpaid interest thereon as of January 28, 2019 (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the related note agreement). We have reserved 1,136,363 shares of the Company’s common stock for issuance under the January 2016 Golisano Warrant. The January 2016 Golisano Warrant, if exercisable, expires on February 28, 2022. The January 2016 Golisano Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

 

In connection with athe Golisano LLC March 21, 2016 Unsecured Promissory Note, we issued into escrow in the name of Golisano LLC a warrant to purchase an aggregate of 3,181,816 shares of the Company’s common stock at an exercise price of $0.01 per share (the “March 2016 Golisano Warrant”). The March 2016 Golisano Warrant will not be released from escrow or be exercisable unless and until we fail to pay Golisano LLC the entire unamortized principal amount of the related promissory note and any accrued and unpaid interest thereon as of March 21, 2019 (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the related note agreement). We have reserved 3,181,816 shares of the Company’s common stock for issuance under the March 2016 Golisano Warrant. The March 2016 Golisano Warrant, if exercisable, expires on March 21, 2022. The March 2016 Golisano Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

In connection with thethe Golisano LLC July 2016 Note, we issued into escrow in the name of Golisano LLC a warrant to purchase an aggregate of 2,168,178 shares of the Company’s common stock, at an exercise price of $0.01 per share (the “Golisano July 2016 Warrant”). The Golisano July 2016 Warrant will not be released from escrow or be exercisable unless and until we fail to pay Golisano LLC the entire unamortized principal amount of the Golisano LLC July 2016 Note and any accrued and unpaid interest thereon as of January 28,July 21, 2019   (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the Golisano LLC July 2016 Note). We have reserved 2,168,178 shares of the Company’s common stock for issuance under the Golisano July 2016 Warrant. The Golisano July 2016 Warrant, if exercisable, expires on July 21, 2022. The Golisano July 2016 Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

19

 

In connection with thethe Golisano LLC December 2016 Note, we issued into escrow in the name of Golisano LLC a warrant to purchase an aggregate of 1,136,363 shares of the Company’s common stock, at an exercise price of $0.01 per share (the “Golisano December 2016 Warrant”). The Golisano December 2016 Warrant will not be released from escrow or be exercisable unless and until we fail to pay Golisano LLC the entire unamortized principal amount of the Golisano LLC December 2016 Note and any accrued and unpaid interest thereon as of December 30,31, 2019, (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the Golisano LLC December 2016 Note)note). We have reserved 1,136,363 shares of the Company’s common stock for issuance under the Golisano December 2016 Warrant. The Golisano December 2016 Warrant, if exercisable, expires on December 30, 2022. The Golisano December 2016 Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.


 

In connection with thethe Golisano LLC March 2017 Note, we issued into escrow in the name of Golisano LLC a warrant to purchase an aggregate of 1,484,847 shares of the Company’s common stock, at an exercise price of $0.01 per share (the “Golisano March 2017 Warrant”). The Golisano March 2017 Warrant will not be released from escrow or be exercisable unless and until we fail to pay Golisano LLC the entire unamortized principal amount of the Golisano LLC March 2017 Note and any accrued and unpaid interest thereon as of December 30,31, 2019 (which has been extended to October 22, 2021 – See Note 6) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the Golisano LLC March 2017 Note). We have reserved 1,484,847 shares of the Company’s common stock for issuance under the Golisano March 2017 Warrant. The Golisano March 2017 Warrant, if exercisable, expires on March 14, 2023. The Golisano March 2017 Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

In connection with the Golisano LLC February 2018 Note, we issued into escrow in the name of Golisano LLC a warrant to purchase an aggregate of 1,818,182 shares of the Company’s common stock at an exercise price of $0.01 per share (the "Golisano 2018 Warrant"). The Golisano 2018 Warrant will not be released from escrow or be exercisable unless and until the Company fails to pay Golisano LLC the entire unamortized principal amount of the Golisano LLC February 2018 Note and any accrued and unpaid interest thereon as of February 6, 2021, (which has been extended to October 22, 2021 – See Note 6) or such earlier date as is required pursuant to an acceleration notice. The Company has reserved 1,818,182 shares of the Company’s common stock for issuance under the Golisano 2018 Warrant. The Golisano February 2018 Warrant expires on February 6, 2024. 

 

We previously entered into a registration rights agreement with Golisano LLC, dated as of October 5, 2015 (the “Registration Rights Agreement”), granting Golisano LLC certain registration rights for certain shares of the Company’s common stock. The shares of common stock issuable pursuant to the above Golisano LLC warrants are also entitled to the benefits of the Registration Rights Agreement.

GH Escrow Warrants

In connection with a January 28, 2016 Unsecured PromissoryGH Note, we issued into escrow in the name of GH a warrant to purchase an aggregate of 1,136,363 shares of the Company’s common stock at an exercise price of $0.01 per share (the “January 2016 GH Warrant”). The January 2016 GH Warrant will not be released from escrow or be exercisable unless and until we fail to pay GH the entire unamortized principal amount of the related promissory noteJanuary 2016 GH Note and any accrued and unpaid interest thereon as of January 28, 2019 (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the related note agreement)January 2016 GH Note). We have reserved 1,136,363 shares of the Company’s common stock for issuance under the January 2016 GH warrant.Warrant. The January 2016 GH Warrant, if exercisable, expires on February 28, 2022. The January 2016 GH Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

20

 

In connection with a March 21, 2016 Unsecured PromissoryGH Note, we issued into escrow in the name of GH a warrant to purchase an aggregate of 3,181,816 shares of the Company’s common stock at an exercise price of $0.01 per share (the “March 2016 GH Warrant”). The March 2016 GH Warrant will not be released from escrow or be exercisable unless and until we fail to pay GH the entire unamortized principal amount of the related promissory noteMarch 2016 GH Note and any accrued and unpaid interest thereon as of March 21, 2019 (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the related note agreement)March 2016 GH Note). We have reserved 3,181,816 shares of the Company’s common stock for issuance under the March 2016 GH Warrant. The March 2016 GH Warrant, if exercisable, expires on March 21, 2022. The March 2016 GH Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

 

In connection with the GHthe December 2016 GH Note, we issued into escrow in the name of GH a warrant to purchase an aggregate of 1,136,363 shares of the Company’s common stock, at an exercise price of $0.01 per share (the “December 2016 GH Warrant”). The December 2016 GH Warrant will not be released from escrow or be exercisable unless and until we fail to pay GH the entire unamortized principal amount of the December 2016 GH WarrantNote and any accrued and unpaid interest thereon as of December 30,31, 2019 (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the December 2016 GH Warrant)Note). We have reserved 1,136,363 shares of common stock for issuance under the December 2016 GH Warrant. The December 2016 GH Warrant, if exercisable, expires on December 30, 2022. The December 2016 GH Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

 

In connection with the GHthe August 2017 GH Note, we issued into escrow in the name of GH a warrant to purchase an aggregate of 1,363,636 shares of the Company’s common stock, at an exercise price of $0.01 per share (the “August 2017 GH Warrant”). The August 2017 GH Warrant will not be released from escrow or be exercisable unless and until we fail to pay GH the entire unamortized principal amount of the August 2017 GH WarrantNote and any accrued and unpaid interest thereon as of August 29, 2020 (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the August 2017 GH Warrant)Note). We have reserved 1,363,636 shares of common stock for issuance under the August 2017 GH Warrant. The August 2017 GH Warrant, if exercisable, expires on August 30, 2023. The August 2017 GH Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.

 


JL-US Escrow Warrant

In connection with an April 5, 2016 Unsecured Promissorythe February 2018 GH Note, we issued into escrow in the name of JL-USGH a warrant to purchase an aggregate of 227,2731,818,182 shares of the Company’sCompany’s common stock at an exercise price of $0.01 per share (the “JL-US Warrant”"February 2018 GH Warrant"). The JL-USFebruary 2018 GH Warrant will not be released from escrow or be exercisable unless and until we failthe Company fails to pay JL-USGH the entire unamortized principal amount of the JL-US Notenote and any accrued and unpaid interest thereon as of March 21, 2019February 6, 2021, (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Notice (as defined in the JL-US Note). We haveacceleration notice. The Company has reserved 227,2731,818,182 shares of the Company’s common stock for issuance under the JL-USFebruary 2018 GH Warrant. The JL-USFebruary 2018 GH Warrant if exercisable, expires on March 21, 2022. The JL-US Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets.February 6, 2024.  

 

Little Harbor Escrow Warrant

The Little Harbor July 2016Delayed Draw Note providesrequired that we issue into escrow in the name of Little Harbor a warrant to purchase an aggregate of 2,168,178 shares of common stock at an exercise price of $0.01 per share (the “Little Harbor July 2016 Warrant”). The Little Harbor July 2016 Warrant will not be released from escrow or be exercisable unless and until we fail to pay Little Harbor the entire unamortized principal amount of the Little Harbor July 2016Delayed Draw Note and any accrued and unpaid interest thereon as of January 28, 2019 (which has been extended to October 22, 2021 – See Note 5) or such earlier date as is required pursuant to an Acceleration Noticeacceleration notice (as defined in the Little Harbor July 2016Delayed Draw Note). We have reserved 2,168,178 shares of the Company’s common stock for issuance under the Little Harbor July 2016 Warrant. The Little Harbor July 2016 Warrant, if exercisable, expires on July 21, 2022. The Little Harbor July 2016 Warrant is also subject to customary adjustments upon any recapitalization, capital reorganization or reclassification, consolidation, merger or transfer of all or substantially all of our assets. The Little Harbor July 2016 Warrant grants Little Harbor certain registration rights for the shares of the Company’s common stock issuable upon exercise of the Little Harbor July 2016 Warrant.

 

21

NOTE N8ote 7 DERIVATIVE LIABILITDIESerivative Liabilities

 

The number of shares of common stock issuable pursuant to certain warrants issued in 2015 will be increasedwere subject to increase if our adjusted EBITDA or the market price of the Company’s common stock doesdid not meet certain defined amounts. We have recorded the estimated fair value of the warrants as of the date of issuance. Due to the variable terms of the warrant agreements, the warrants arewere recorded as derivative liabilities with a corresponding chargegain or loss recorded to our condensed consolidated statements of comprehensive loss for changes in the estimated fair value of the warrants from the date of issuance to each balance sheet reporting date. As of September 30, 2017, we have2020, all the associated warrants were either exercised or expired, and therefore the value of the derivative liabilities was zero. We estimated the total fair value of the derivative liabilities to be $8,143 as compared to $6,455$35 as of December 31, 2016.2019. We had the following activity in our derivative liabilities account since December 31, 2016:for the nine months ended September 30, 2020:

 

  

Nine Months Ended

 
  

September 30,

 
  

2017

 

Derivative liabilities at December 31, 2016

 $6,455 
     

Loss on change in fair value of derivative liabilities

  1,688 

Derivative liabilities at September 30, 2017

 $8,143 

Derivative liabilities as of December 31, 2019

 $35 

Gain on change in fair value of derivative liabilities

  (35)
     

Derivative liabilities as of September 30, 2020

 $- 

 

The value of the derivative liabilities iswas generally estimated using an options lattice model with multiple inputs and assumptions, including the market price of the Company’sCompany’s common stock, stock price volatility and other assumptions to project EBITDA and other reset events. These inputs and assumptions arewere subject to management’s judgment and can vary materially from period to period.judgment.

Note 8Leases

 

The Company leases office space under non-cancelable operating leases with lease terms ranging from 1 to 7 years. These leases require monthly lease payments that may be subject to annual increases throughout the lease term.  Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional 2 to 5 years. These optional periods have not been considered in the determination of the right-of-use assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined each of its identified leases are operating leases.

For the three months and nine months ended September 30, 2020, the Company incurred $236 and $858, respectively, of lease expense on the condensed consolidated statements of operations in relation to these operating leases, of which $51 and $246, respectively, was variable rent expense associated with capitalized operating leases and not included within the measurement of the Company's operating right-of-use assets and lease liabilities. The variable rent expense consists primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components.  

As of September 30, 2020, the maturities of the Company’s lease liabilities were as follows:

2020 (excluding the nine months ended September 30, 2020)

 $323 

2021

  1,144 

2022

  1,052 

2023

  1,079 

2024

  1,108 

Thereafter

  2,395 

 Total lease payments

  7,101 

   Less: imputed interest

  (1,554)

  Present value of lease liabilities

 $5,547 

22

Included below is other information regarding leases for the three-month and nine-month periods ended September 30, 2020.

  

Three Months Ended
September 30, 2020

  

Nine Months Ended
September 30, 2020

 

Sublease income

 $189  $565 

Cash paid for operating leases

 $322  $956 

Weighted average remaining lease term (years) - operating leases

  6.2   6.2 

Weighted average discount rate – operating leases

  8.25%  8.25%

As previously disclosed in our financial statements for the year ended December 31, 2019, future minimum lease payments under ASC 840 for operating leases were as follows:

Years Ending December 31,

 

Operating Leases

 
     

2020

 $1,280 

2021

  1,144 

2022

  1,052 

2023

  1,079 

2024

  1,108 

Thereafter

  2,394 
     
  $8,057 

NOTE Note 9 STOCKHOLDERS’ Stockholders’ DeficitEQUITY (DEFICIT)

 

Preferred Stock

The Company has authorized 500,000,000 shares of preferred stock with a par value of $0.001 per share. No shares of the preferred stock have been issued.

Twinlab Consolidation Corporation 2013 Stock Incentive Plan

The only equity compensation plan currently in effect is the Twinlab Consolidation Corporation 2013 Stock Incentive Plan (the “TCC Plan”), which was assumed by the Company on September 16, 2014. The TCC Plan originally established with a pool of 20,000,000 shares of common stock for issuance as incentive awards to employees for the purposes of attracting and retaining qualified employees who will aid in the success of the Company. From January through December 2015, the Company granted restricted stock units to certain employees of the Company pursuant to the TCC Plan. Each restricted stock unit relates to one share of the Company’s common stock. The restricted stock unit awards vest 25% each annually on various dates through 2019.employees. The Company estimated the grant date fair market value per share of the restricted stock units and is amortizingamortized the total estimated grant date value over the vesting periods. During the nine months endedThe restricted stock unit awards vested 25% each annually on various dates through 2019. There were no outstanding or unvested restricted stock units at December 31, 2019 or September 30, 2017, there were not any shares of common stock issued to employees pursuant to the vesting of restricted stock units.2020. As of September 30, 2017, 6,060,9432020, 7,194,412 shares remain available for use in the TCC Plan.


Common Stock Repurchase

On January 5, 2017, pursuant to a repurchase agreement, 642,366 shares of the Company’s common stock were repurchased for an aggregate repurchase price of less than $1.

 

Stock Subscription Receivable and Loss on Stock Price Guarantee

At

As of September 30, 2017,2020, the stock subscription receivable dated August 1, 2014 for the purchase of 1,528,384 shares of the Company’s common stock had a principal balance of $30 and bears interest at an annual rate of 5%.

23

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations (amounts in thousands, except share and per share amounts and number of employees)

 

On August 6, 2016, the 18-month anniversary The following discussion and analysis of the closingour financial condition and results of a share purchase agreement, we were required to pay the purchaser of the common stock the difference between $2.29 per share and either a defined market price or a price per share determined by a valuation firm acceptable to both parties. Based on an outside professional valuation performed on the Company’s common stock, the Company estimated the stock price guarantee payment tooperations should be $3,210. Accordingly, the Company recorded a loss on the stock purchase price guarantee of $3,210 and a corresponding liability for the same amountread in 2016, which was included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of December 31, 2016. On June 2, 2017, the two parties came to an agreement in which we were required to issue the Huntington Note in favor of Huntington. The Huntington Note matures on June 2, 2019conjunction with the principal amount of $3,200 payable at maturity. Interest on the outstanding principal accrues at a rate of 8.5% per year from August 6, 2016 to August 15, 2017,unaudited condensed consolidated financial statements and increases to 10% per year thereafter. We paid $50 to Huntington related to accrued interest from August 6, 2016 through the date of issuance of the Huntington Note. Huntington was required to return 778,385 shares of the Company’s common stock which were issued into escrow. We were required to provide certain piggyback registration rights to Huntingtonnotes included elsewhere in regards to the remaining 749,999 shares of the Company’s common stock held by Huntington. If the Huntington Note was paid off prior to August 14, 2017, the 778,385 shares held in escrow were to be released from escrow and transferred to the Company for no additional consideration. If the note remained outstanding on August 15, 2017, we had the right, but not the obligation, to pay $140 to Huntington to purchase 764,192 of the Subject Shares held in escrow. Upon the exercise of this purchase option, the Subject Shares were to be released from escrow and transferred to the Company. If the note remained outstanding on August 15, 2017 and we did not exercise the option to purchase the shares, the shares were to be returned from escrow to Huntington and we would no longer have repurchase rights. On August 15, 2017, the note was outstanding and we did not excerise the repurchase right. The 778,385 shares were returned from escrow to Huntington. Pursuant to the agreement, we were also required to enter into a four-year lease agreement with the purchaser related to our premises occupied by Nutricap.


Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

(Amounts in thousands, except share and per share amounts and number of employees)

Overview

This Quarterly Report on Form 10-Q containsand our audited financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission (the “SEC”) on May 29, 2020. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements. statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions.Any statements contained herein that are not statements of historical fact, may be deemed to be forward-lookingincluding statements within the meaningregarding guidance, industry prospects or future results of Section 21E of the Securities Exchange Act of 1934,operations or financial position made in this report are forward-looking. We often use words such as amended (the “Exchange Act”). The words “believes,” “anticipates,” “plans,” “expects,” “intends”anticipates, believes, estimates, expects, intends, predicts, hopes, should, plans, will and similar expressions to identify someforward-looking statements. These statements are based on management’s current expectations and accordingly are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained herein due to various important factors, including (but not limited to): the impact of the forward-looking statements. Forward-looking statements are not guaranteesCOVID pandemic; consumer preferences, spending and debt levels; the general economic and credit environment; interest rates; variations in consumer purchasing activities; competitive pressures on sales; the loss of performancea significant customer or future resultsmaterial reduction of business with a significant customer; pricing and involve risks, uncertaintiesgross sales margins; the associated fees or estimated cost savings from contract renegotiations; and assumptions. The factors discussed elsewhere in this Form 10-Qour ability to establish and in subsequent Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K, could also cause actual results to differ materially from those indicated by our forward-looking statements.maintain acceptable commercial terms with contract manufacturers. We undertake no obligation to publicly update or revise any forward-looking statements.statements except as required by law.

 

Our OperationsOverview

 

We are an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores, mass marketmarket retailers, specialty storesstore retailers, on-line retailers and websites. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.

 

Our products include vitamins, minerals, specialty supplements and sports nutrition products primarily under the Twinlab® (including the REAAL®, and Twinlab® Fuel brand of sports nutrition products), Reserveage™ and ResVitale® brands. We also manufacture and sell diet and energy products under the Metabolife® and Re-Body® brands and a full line of herbal teas under the Alvita® brand. To accommodate consumer preferences, our products come in various formulations and delivery forms, including capsules, tablets, softgels,soft gels, chewables, liquids, sprays, powders and whole herbs. These products are sold primarily through health and natural food stores and on-line retailers, supermarkets, and mass-market retailers.

 

We also perform contract manufacturing services for private label products. Our contract manufacturing services business involves the manufacture of custom products to the specifications of a customer who requires finished products under the customer’s own brand name. We do not market these private label products as our business is to manufacture and sell the products to the customer, who then markets and sells the products to retailers or end consumers.

 

We manufacture and/or distribute one of the broadest branded product lines in the industry with approximately 260 stock keeping units, or SKUs. We believe that as a result of our emphasis on innovation, quality, loyalty, education and customer service, our brands are widely recognized in health and natural food stores and among their customers.

 

We have fully integrated our two 2015 acquisitions. The first was the acquisition of the customer relationships of Nutricap, a provider of dietary supplement contract manufacturing services, into our subsidiary, NutraScience, in February 2015, and the second was the acquisition of 100% of the equity interests of Organic Holdings, a market leader in the healthy aging and beauty from within categories and owner of the award-winning Reserveage™ Nutrition brand, in October 2015. Progress has been made in consolidating manufacturing operations and we continue to believe that these acquisitions significantly strengthened our product offerings, contract manufacturing services and our sales and marketing capabilities, providing us with opportunities to improve our market position in addition to adding to supply chain efficiencies.

Going Concern Uncertainty

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. In most periods since our formation, we have generated losses from operations. AtAs of September 30, 2017,2020, we had an accumulated deficit of $237,326.$327,251. Historical losses are primarily attributable to lower than planned sales resulting from low fill rates on demand due to limitations of our working capital, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with our debt refinancing.debt. Losses have been funded primarily through the issuance of common stock, warrants and third-party or related party debt.

 

Because of this history of operating losses, significant interest expense on our debt, and the recording of significant derivative liabilities, we have a working capital deficiency of $8,531 at$108,638 as of September 30, 2017.2020.  We also have $17,091$96,142 of debt, net of discount, due within the next 12 months.presented in current liabilities. These continuing conditions, among others, raise substantial doubt about our ability to continue as a going concern.

 


24

 

Management has taken steps to address operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; reducing manufacturing and operating costs and continuing to negotiate lower prices from major suppliers. During the nine months ended September 30, 2017, we obtained debt funding totaling $6,267 to execute the new supply chain initiatives and increase inventory levels. It is possible that we may need additional capital to execute our business plan. If additional funding is required, there can be no assurance that sources of funding will be available when needed on acceptable terms or at all.

Critical Accounting Policies To meet capital requirements, the Company may consider selling certain assets or seeking financing through a combination of equity offerings, debt financings, collaborations, strategic alliances and Estimates

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which we have prepared in accordance with the U.S. generally accepted accounting principles. The preparation of our financial statements required us to make estimates and assumptions that affected the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Significant estimates include values and lives assigned to acquired intangible assets, reserves for customer returns and allowances, uncollectible accounts receivable, valuation adjustments for slow moving, obsolete and/or damaged inventory and valuation, recoverability of long-lived assets, intangibles and goodwill, estimated values of stock options and warrants, share-based compensation, and the identification and valuation of derivatives. Actual results may differ from these estimates.

Our critical accounting policies and estimates include the following:

Revenue Recognition

Revenue from product sales, net of estimated returns and allowances, is recognized when evidence of an arrangement is in place, related prices are fixed and determinable, contractual obligations have been satisfied, title and risk of loss have been transferred to the customer and collection of the resulting receivable is reasonably assured. Shipping terms are generally freight on board shipping point. We sell predominately in the North American and European markets, with international sales transacted in U.S. Dollars.

Accounts Receivable and Allowances

We grant credit to customers and generally do not require collateral or other security. We perform credit evaluations of our customers and provide for expected claims, related to promotional items; customer discounts; shipping shortages and damages; and doubtful accounts based upon historical bad debt and claims experience.

Inventories

Inventories are stated at the lower of cost or net realizable value and are reduced by an estimated reserve for obsolete inventory.

Intangible Assets

Intangible assets consist primarily of trademarks and customer relationships, which are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 30 years. The valuation and classification of these assets and the assignment of amortizable lives involve significant judgment and the use of estimates.

We believe that our long-term growth strategy supports our fair value conclusions. For intangible assets, the recoverability of these amounts is dependent upon achievement of our projections and the execution of key initiatives related to revenue growth and improved profitability.

Goodwill

Goodwill is not subject to amortization, but is reviewed for impairment annually, or more frequently whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable. An impairment charge would be recorded to the extent the carrying value of goodwill exceeds its estimated fair value. The testing of goodwill under established guidelines for impairment requires significant use of judgment and assumptions. Changes in forecasted operations and other assumptions could materially affect the estimated fair values. Changes in business conditions could potentially require adjustments to these asset valuations.


Impairment of Long-Lived Assets

Long-lived assets, including intangible assets subject to amortization, are reviewed for impairment when changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If the carrying amount of the asset exceeds the expected undiscounted cash flows of the asset, an impairment charge is recognized equal to the amount by which the carrying amount exceeds fair value. The testing of these intangibles under established guidelines for impairment requires significant use of judgment and assumptions. Changes in forecasted operations and other assumptions could materially affect the estimated fair values. Changes in business conditions could potentially require adjustments to these asset valuations.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets relating to the asset acquisition of Organic Holdings are determined to have an indefinite useful economic life and as such are not amortized. Indefinite-lived intangible assets are tested for impairment annually which consists of a comparison of the fair value of the asset with its carrying value.

Value of Warrants Issued with Debt

We estimate the grant date value of certain warrants issued with debt, using an outside professional valuation firm, which uses the Monte Carlo option lattice model. We record the amounts as interest expense or debt discount, depending on the terms of the agreement. These estimates involve multiple inputs and assumptions, including the market price of the Company’s common stock, stock price volatility and other assumptions to project earnings before interest, taxes, depreciation and amortization (“EBITDA”) and other reset events. These inputs and assumptions are subject to management’s judgment and can vary materially from period to period.

Derivative Liabilities

We have recorded certain warrants as derivative liabilities at estimated fair value, as determined based on the Company’s use of an outside professional valuation firm, due to the variable terms of the warrantlicensing agreements. The value of the derivative liabilities is generally estimated using Monte Carlo option lattice model with multiple inputs and assumptions, including the market price of the Company’s common stock, stock price volatility and other assumptions to project EBITDA and other reset events. These inputs and assumptions are subject to management’s judgment and can vary materially from period to period.

Share-Based Compensation

We record share-based compensation, including grants of restricted stock units, based on their grant date fair values and record compensation expense over the vesting period of the restricted stock awards.

Income Taxes

We account for income taxes using an asset and liability approach. Deferred income taxes are determined by applying currently enacted tax laws and rates to the cumulative temporary differences between the carrying values of assets and liabilities for financial statement and income tax purposes. Valuation allowances against deferred tax assets are recorded when we are unable to conclude that it is more likely than not that such deferred tax assets will be realized.

 

Results of Operations

 

Comparison of the Three and Nine Month Periods Ended September 30, 2020 and 2019

The following table summarizes our results of operations for the three and nine month periods ended September 30, 2020 and 2019:

  

Three Months Ended
September 30,

  

Increase

  

%

  

Nine Months Ended
September 30,

  

Increase

  

%

 
  

2020

  

2019

  

(Decrease)

  

Change

  

2020

  

2019

  

(Decrease)

  

Change

 

Net sales

 $18,371  $19,851  $(1,480)  -7% $47,012  $57,558  $(10,546)  -18%

Cost of sales

  14,669   18,188   (3,519)  -19%  35,322   48,227   (12,905)  -27%

Gross profit

  3,702   1,663   2,039   123%  11,690   9,331   2,359   25%

Operating costs and expenses:

                                

Selling expenses

  420   1,300   (880)  -68%  1,044   1,412   (368)  -26%

General and administrative expenses

  2,981   4,198   (1,217)  -29%  12,567   16,933   (4,366)  -26%

Income (loss) from operations

  301   (3,835)  4,136   108%  (1,921)  (9,014)  7,093   79%
                                 

Other income (expense):

                                

Interest expense, net

  (2,183)  (2,154)  29   1%  (6,489)  (7,580)  (1,091)  -14%

Gain (loss) on change in derivative liabilities

  178   2,789   (2,611)  -94%  35   474   (439)  -93%

Other expense

  (148)  (16)  132   825%  (3)  (36)  (33)  -92%

Loss on disposition of property and equipment

  -   -   -   0%  -   (386)  386   100%

Total other income (expense)

  (2,153)  619   (2,772)  -448%  (6,457)  (7,528)  1,071   14%
                                 

Loss before income taxes

  (1,852)  (3,216)  (1,364)  -42%  (8,378)  (16,542)  (8,164)  -49%
                                 

Provision for income taxes

  -   -           -   -         
                                 

Total net loss

 $(1,852) $(3,216) $(1,364)  -42% $(8,378) $(16,542) $(8,164)  -49%

Net Sales

Our

The decrease in our net sales by 7% and 18% for the three and nine month periods ended September 30, 2020 compared to the same periods in 2019, respectively, is primarily due to our focusing on fewer inventory SKUs and changing customer base, as well as the impacts of the COVID-19 pandemic.

Gross Profit

Our overall gross profit increase of 123% and 25% for the three and nine month periods ended September 30, 2020 compared to the same periods in 2019, respectively, was primarily due to a focus on fewer SKUs with higher margins offset by shifts in the margin mix of sales.

Selling Expenses

Our selling expenses decreased $2,434,by 68% and 26% for the three and nine month periods ended September 30, 2020 compared to the same periods in 2019, respectively, primarily due to reduced advertising and marketing campaigns related to the targeted SKUs and customer base.

General and Administrative Expenses

Our general and administrative expenses decreased by 29% and 26% for the three and nine month periods ended September 30, 2020 compared to the same period in 2019, respectively, due to the Company’s rightsizing initiatives.

25

Interest Expense, Net

Our interest expense was relatively unchanged with a $29 or 11%, to $20,6121% increase for the three months ended September 30, 2017 from $23,046 for the three months ended September 30, 2016. On a year-to-date basis, our net sales increased $245, or 0%,2020 compared to $66,130 for the nine months ended September 30, 2017 from $65,885 for the nine months ended September 30, 2016. The decrease in our net sales for the three months ended September 30, 2017 reflects the decision to exit certain lower margin contract manufacturing business at Twinlab and lower Twinlab branded sales due to lost distribution from out-of-stock conditions caused by order fulfillment shortfalls during 2016. Our net sales for the nine months ended September 30, 2017 increased due to organic growth in Nutrascience’s contract manufacturing business.

Gross Profit

Our gross profit decreased $3,574, or 50%, to $3,509 for the three months ended September 30, 2017 from $7,083 for the three months ended September 30, 2016.  On a year-to-date basis, our gross profit decreased $718, or 4%, to $15,762 for the nine months ended September 30, 2017 from $16,480 for the nine months ended September 30, 2016. The decrease in our gross profit for the three months ended September 30, 2017 is derived from lower net sales as well as one-time inventory write-offs. The decrease in our gross profit for the nine months ended September 30, 2017 is derived from one-time inventory write-offs.


Selling, General and Administrative Expenses

Our selling, general and administrative expenses decreased $1,114, or 14%, to $6,646 for the three months ended September 30, 2017 from $7,760 for the three months ended September 30, 2016. On a year-to-date basis, our selling, general and administrative expenses decreased $5,675, or approximately 22%, to $20,574 for the nine months ended September 30, 2017 from $26,249 for the nine months ended September 30, 2016. The decreases in our selling, general and administrative expenses are primarily due to our reduction in force to right-size the number of employees which began in 2016.

Loss on Stock Purchase Price Guarantee

On August 6, 2016, the 18-month anniversary of the closing of a share purchase agreement, we were required to pay the purchaser of the common stock the difference between $2.29 per share and either a defined market price or a price per share determined by a valuation firm acceptable to both parties. Based on an outside professional valuation performed on the Company’s common stock, the Company estimated the stock price guarantee payment to be $3,210. Accordingly, the Company recorded a loss on the stock purchase price guarantee of $3,210 and a corresponding liability for the same amount in 2016, which was included in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of December 31, 2016.  On June 2, 2017, the two parties came to an agreement in which we were required to issue an Unsecured Promissory Note (“Huntington Note”) in favor of Huntington Holdings, LLC (“Huntington”). The Huntington Note matures on June 2, 2019 with the principal amount of $3,200 payable at maturity. Interest on the outstanding principal accrued at a rate of 8.5% perprior year from August 6, 2016 to August 15, 2017, and increased to 10% per year thereafter. We paid $50 to Huntington related to accrued interest from August 6, 2016 through the date of issuance of the Huntington Note. Huntington was required to return 778,385 shares of the Company’s common stock which were issued into escrow. We were required to provide certain piggyback registration rights to Huntington in regards to the remaining 749,999 shares of the Company’s common stock held by Huntington. If the Huntington Note was paid off prior to August 14, 2017, the 778,385 shares held in escrow were to be released from escrow and transferred to the Company for no additional consideration. If the note remained outstanding on August 15, 2017, we had the right, but not the obligation, to pay $140 to Huntington to purchase 764,192 of the Subject Shares held in escrow. Upon the exercise of this purchase option, the Subject Shares were to be released from escrow and transferred to the Company.  If the Huntington Note remained outstanding on August 15, 2017 and we did not exercise the option to purchase the shares, the shares were to be returned from escrow to Huntington and we would no longer have repurchase rights. On August 15, 2017, the note was outstanding and we did not excerise the repurchase right. The 778,385 shares were returned from escrow to Huntington.

Interest Expense, Net

Our interest expense decreased $547, or 23%, to $1,876 for the three months ended September 30, 2017 from $2,423 for the three months ended September 30, 2016.period. On a year-to-date basis, our interest expense decreased $212,by $1.1 million, or 3%14%, to $6,318 for the nine months ended September 30, 2017 from $6,530 for2020 compared to the nine months ended September 30, 2016.same period in 2019. The decrease in our interest expense is primarily due to a decreasedebt reductions in our note discounts2020 compared to increased debt in the first quarter of 2019, including the payoff of the Huntington Holdings debt, as well as extension of the debt maturities, which are amortized intodecreased the monthly amount of interest expense.recognized from debt discount amortization.

 

Gain (Loss) on ChangeChange in Derivative Liabilities

The number of shares of common stock issuable pursuant to certain warrants issued in 2015 will be increased if our audited adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) or the market price of the Company’s common stock do not meet certain defined amounts.

We have recorded the estimated fair value of the warrants as of the date of issuance and each subsequent balance sheet reporting date.issuance. Due to the variable terms of the warrant agreements, changes in the estimated fair value of the warrants from the date of issuance to each balance sheet reporting date are recorded as gain (loss) on change in derivative liabilities inwith a corresponding charge to our condensed consolidated statements of comprehensive loss. During the three months and nine months endedoperations. As of September 30, 2017, we reported a loss on change2020, none of the warrants that resulted in the recording of the related derivative liabilities of $393 and $1,688, respectively. During the three and nine months ended September 30, 2016, we reported a gain on change in derivative liabilities of $14,065 and $28,128, respectively.is outstanding.

 

Liquidity and Capital Resources

 

At September 30, 2017,2020, we had an accumulated deficit of $237,326,$327.3 million primarily because of our history of operating losses and our recording of derivative liabilities and loss on a stock purchase price guarantee. We have a working capital deficiency of $8,531$108,638 at September 30, 2017.2020. Losses have been funded primarily through the issuance of common stock and warrants, borrowings from our stockholders and third-party or related party debt and proceeds from the exercise of warrants. As of September 30, 2017,2020, we had cash of $2,233.$877. On an ongoing basis, we also seek to improve operating cash through trade receivables and payables management as well as inventory stocking levels. We used net cash in operating activities of $9,143$4,408 for the nine months ended September 30, 2017.2020. During the nine months ended September 30, 2017,2020, we incurred new debt of $6,267, had a net increase in borrowings onfrom our senior credit facility of $1,646 to fund our operations$671 and debt repayment of $1,583.$2,310.


 

Our total liabilities increased by $8,774$14.5 million to $99,834$132.6 million at September 30, 20172020 from $91,060$118.1 million at December 31, 2016.2019. This increase in our total liabilities was primarily due to an increase in our non-cash derivative liabilities of $1,688, a non-cash increase in our debt of $3,530, a decrease in our liabilities related to operations of $4,548 and a netthe increase of $8,104$5.8 million in debt. For discussionnotes payable and $5.5 million in lease liabilities with the adoption of our debt financings completed to date during 2017, see Notes 6 and 7 in the Notes to Condensed Consolidated Financial Statements included in this report.ASC 842.

 

Cash Flows from Operating, Investing and Financing Activities

Net cash used in operating activities was $9,143$4.4 million for the nine months ended September 30, 20172020 as a result of our net loss of $12,854,$8.4 million, a recovery for losses on accounts receivable of $3,251 in doubtful accounts receivable, a non-cash lossgain on change in derivative liabilities of $1,688, as well as$35, other non-cash expenses totaling $5,088$1,981 net and an increase in net operating assets and liabilities of $3,065.$5,275. By comparison, for the nine months ended September 30, 2016,2019, net cash used in operating activities was $20,535$7.7 million as a result of our net incomeloss of $8,584,$16.5 million, a provision for losses on accounts receivable of $2,700, a non-cash gain on change in derivative liabilities of $28,128 as well as$474, a loss on disposal of property and equipment of $386, other non-cash expenses totaling $10,016$3,087 net and aan increase in net operating assets and liabilities of $11,007. See Condensed Consolidated Statements of Cash Flows included in this report for additional information.

Net cash used in investing activities for the nine months ended September 30, 2017 and 2016 was $51 and $119, respectively, consisting of the purchase of property and equipment.$3,121.

 

Net cash provided by financing activities was $6,330$5,035 for the nine months ended September 30, 2017, primarily2020, consisting of net borrowings of $671 under our revolving credit facility, proceeds from the issuance of debt of $6,267, net borrowings of $1,646 under our revolving credit facilities, partially offset by$6,674, and repayment of debt of $1,583. Net cash provided by$2,310.

Ongoing Funding Requirements

As set forth above, we obtained additional debt financing activities was $22,459 forin the nine months ended September 30, 2016, consisting of proceeds from the issuance of debt of $22,089, net borrowings of $3,342 under our revolving credit facilities, partially offset by repayment of debt of $2,973.

Ongoing Funding Requirements

As set forth above, we have obtained additional debt financing to date in 20172020 to support operations. It is possible that we may need additional funding to enable us to fund our operating expenses and capital expenditure requirements.

26

In response to COVID-19 and to protect our liquidity and cash position, we have taken a number of steps. In August of 2020, we obtained deferment letters from each of Great Harbor, Little Harbor and Golisano Holdings pursuant to which each lender agreed to defer all payments due under outstanding notes held by each lender through October 22, 2021 and agreed to refrain from declaring a default and/or exercising any remedies under the outstanding notes.  On May 7, 2020, TCC, the operating subsidiary of the Company, received the proceeds of a loan from Fifth Third Bank, National Association in the amount of $1,674 obtained under the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted March 27, 2020 (the "PPP Loan”). The PPP Loan, evidenced by a promissory note dated May 5, 2020 (the “Note”), has a two-year term and bears interest at a rate of 1.0% per annum, with the monthly principal and interest payments due beginning December 1, 2020. TCC may prepay 20% or less of the principal balance of the Note at any time without notice. TCC will use the proceeds of the PPP Loan for payroll, office rent, and utilities. While we intend to pursue the forgiveness of the PPP loans received in accordance with the requirements and limitations under the CARES Act, no assurance can be provided that forgiveness of any portion of the PPP Loan will be obtained.

 

Until such time, if ever, as we can generate substantial product revenues, we intend to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. There can be no assurance that any of those sources of funding will be available when needed on acceptable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or relationships with third parties when needed or on acceptable terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts; abandon our business strategy of growth through acquisitions; or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

  

Recent Accounting Pronouncements

In May 2017, FASB amended its guidance regarding the scope of modification accounting for share-based compensation arrangements. The amendments provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. For public entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, with early adoption permitted. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. We do not expect the new guidance to have a significant impact on our condensed consolidated financial statements or related disclosures.

In January 2017, FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill Impairment (Topic 350)” which removes Step 2 of the goodwill impairment test that requires a hypothetical purchase price allocation.  A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill.  The amendments in this ASU are effective for fiscal years beginning after December 15, 2019.  Early adoption is permitted after January 1, 2017.  We do not expect the new guidance to have a significant impact on our condensed consolidated financial statements or related disclosures.


In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”. The amendments in this ASU revise the accounting related to lessee accounting. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases with terms greater than 12 months affecting the pattern of expense recognition in the income statement. Leases previously defined as operating leases will be defined as financing leases and capitalized if the term is greater than one year. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018 and are to be applied through a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are performing an assessment of our leases and have begun preparations for implementation and retrospective application to the earliest reporting period. As a result, financing leases will be recorded as an asset and a corresponding liability at the present value of the total lease payments. The asset will be decremented over the life of the lease on a pro-rata basis resulting in lease expense while the liability will be decremented using the interest method (ie. principal and interest). As such, we expect the new guidance will materially impact the asset and liability balances of our consolidated financial statements and related disclosures at the time of adoption.

Although there are several other new accounting pronouncements issued or proposed by FASB, which we have adopted or will adopt, as applicable, we do not believe any of these accounting pronouncements has had or will have a material impact on our condensed consolidated financial position or results of operations.

Material Contractual Obligations

On December 15, 2016, we entered into an operating lease agreement for approximately 13,000 square feet of office space in Boca Raton, Florida. The agreement expires 103 months after the commencement, which occured in August 2017, and has a monthly base rent of $17.

As of September 30, 2017, we have total debt of $74,253, of which $54,174 is considered to be related-party debt. For discussion of our debt financings, see Notes 6 and 7 in the Notes to Condensed Consolidated Financial Statements included in this report.

Effective February 6, 2013, we entered into an operating lease agreement for approximately 170,000 square feet of manufacturing, research and development, warehousing and shipping space, which includes roughly 30,000 square feet of office space, in American Fork, Utah. The agreement expires in February 2028 and has a monthly base rent of $60, provided that commencing on the five-year anniversary date thereafter, the base rent shall be increased by 10% over the base rent for the preceding five-year period.

Effective April 7, 2015, we entered into an operating lease agreement for approximately 31,000 square feet of office space in St. Petersburg, Florida. The agreement expires in April 2027 and has a monthly base rent of $59 for year 1 to $76 for year 12.

Off-Balance Sheet Arrangements

 

None.We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.

 

Item 3.Quantitative and Qualitative DisclosuresDisclosures About Market Risk.Risk.

 

This item is not applicable as we are currently considered a smaller reporting company.

 

Item 4.Controls and Procedures.Procedures. 

 

Evaluation of Disclosure Controls and Procedures

 

Our management,, with the participation of our chiefprincipal executive officer and our chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2017,2020 pursuant to Rule 13a-15(b)13a-15(e) and 15d-15(e) under the Securities Exchange Act.Act of 1934, as amended. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’sSEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.


Based on On the evaluationbasis of our disclosure controls and procedures as of September 30, 2017,this review, our management, including our principal executive officer and chief financial officer, has concluded that as a result of material weaknesses in our internal control over financial reporting discussed below,the end of the period covered by this report, our disclosure controls and procedures were not effective asto give reasonable assurance that the information required to be disclosed in our reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of September 30, 2017. the SEC, and to ensure that the information required to be disclosed in the reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and chief financial officer, in a manner that allows timely decisions regarding required disclosure.

 

Management’s Remediation Initiatives

27

 

Management plansDuring the fourth quarter of 2018, management identified material weaknesses in the selection and has initiated actions to implement a number of initiatives that address the ineffective design of the system of internal control over financial reporting and plans to initiate further actions to implement a number of initiatives, including but not limited to the following:

Work throughout the year with our independent Sarbanes-Oxley Act consultant to help improve the overall testing of our system of internal control over financial reporting, so we promptly identifythird-party logistics (“3PL”) and refine priorfulfillment provider, whom the Company engaged to year-end.

Continue to evaluate control procedures on an ongoing basis, and, where possible modify those control procedures to improve management oversight.

Implement and improve systems to automate certain financial reporting processes and to improve information accuracy.

We made various staff changes during 2017 in our finance and accounting department and we believe these changes have enabled us to broadenreplace the scope and quality of our controls relatingCompany's Utah manufacturing facility. The Company has determined that the 3PL does not issue reports pursuant to the oversightStatement on Standards for Attestation Engagement No. 18 attestation standards (“SSAE 18”). The Company should have designed and review of financial statements and to properly apply all relevant accounting. Furthermore, we plan to implement and improve systems to automate certain financial reporting processes and to improve information accuracy.

Management will continueimplemented the process of reviewing existing controls, procedures and responsibilities to more closely identify financial reporting risks and the requirednecessary internal controls to address them. Key controlthe potential risks of using a 3PL who does not issue SSAE18 reports. The Company should have taken steps to design and compensating control procedures have been developedimplement controls around the receipt of inventory at the 3PL to ensure thatthe quantities and description of inventory movements related to the 3PL. Additionally, the Company should take steps to obtain and review the appropriate SSAE 18 reports issued by the software company which the 3PL uses as its inventory management software. Management also identified a material weakness related to a lack of appropriate staffing in our accounting and information technology departments to address the Company's ability to continue to close the books both timely and accurately and to meet internal control documentation requirements. Prior normal staffing turnover along with technical accounting issues and the Company's change to a 3PL impacted the Company's ability to react to technical accounting matters encountered.

During the first quarter of 2020, management identified material weaknesses are properly addressed and related to our financial reporting risks are mitigated. Periodicprocedures which resulted in the Company not properly recording a reserve for accounts receivable related to a significant customer that had recently entered bankruptcy proceedings. This material weakness caused the Company to have to amend its 2020 first quarter 10-Q on August 17, 2020 to properly state our financial position. Management believes that this control validation and testingfailure has been implemented to ensure that controls continue to operate consistentlyresolved with staffing changes and as designed. The remediation stepssystem improvements.

Although we have taken, are taking and expect to take may not effectivelyimplemented certain measures that we believe will remediate thethese material weaknesses, in which casewe can provide no assurance that our internal control over financial reporting would continue toremediation efforts will be ineffective. Even if we are able to complete these actions successfully, these measures may not adequately address our material weaknesses and may take additional time to complete. In addition, it is possibleeffective or that we will discover additional material weaknesses in our internal control over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties that our existing material weaknesses willmay be encountered in their implementation, could result in additional errorsmaterial weaknesses, cause us to fail to meet our periodic or annual reporting obligations or result in or restatements ofmaterial misstatements in our financial statements. Any such failure could also adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control over financial reporting required under Section 404 of the Sarbanes Oxley Act of 2002 and the rules promulgated thereunder. The existence of material weaknesses could result in errors in our financial statements that could result in a restatement of those financial statements.

 

Changes in Internal Control over Financial ReportingLimitations on Effectiveness of Controls and Procedures

 

Other than The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the items discussed above, thereexercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but we cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting. 

There were no changes in our internal controlcontrols over financial reporting during our most recent fiscalthe quarter ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal controlcontrols over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 


28

 

PART IIII. – OTHER INFORMATION

 

Item 1.     Legal Proceedings

 

In re: Herbal Supplements MarketingFrom time to time, we may become involved in various lawsuits and Sales Practicelegal proceedings, which arise in the ordinary course of business. Litigation MDL No. 2619, Case No. 1:15-cv-5070, U.S. District Court for the Northern District of Illinois, filed on June 9, 2015. We are not a partyis subject to this matter, which joinedinherent uncertainties, and an adverse result in a multidistrict litigation a number of purported class actions arisingthese or other matters may arise from allegations raised by a state attorney general claimingtime to time that DNA barcoding testing conducted on behalfmay harm our business. As of the attorney general indicated that certain herbal supplement products did not contain the herbal ingredients stated on the label. We do, however, pursuant to contractual obligations, provide indemnity and defense with respect to certain of the claims in this litigation. The defendants in this litigation intend to take all necessary steps to vigorously defend this matter.

Amy Mathews v. Wal-Mart Stores, Inc. and Wal-Mart Stores Arkansas LLC, Case No. CV-2015-0294, in the Circuit Court of Independence County, Arkansas, Civil Division. This purported class action alleges a violation of the Arkansas Deceptive Trade Practices Act based on the same allegations of the state attorney general that serve as the basis for the claims in the Herbal Supplements multidistrict litigation referenced above, and seeks certification of a class of Arkansas residents purportedly impacted by the allegations. We are not a party to this litigation but provide indemnity and defense with respect to certain of the claims in this litigation.

Corr-Jensen Inc. v. Mark Walsh and Twinlab Corporation, Case No. 1:17-cv-01473-CBS, in the U.S. District Court for the District of Colorado, filed on June 16, 2017. The plaintiff, Corr-Jensen Inc., alleges Twinlab Corporation intentionally and improperly interfered with Mr. Walsh’s employment agreement and release with the plaintiff by allegedly engaging Mr. Walsh or continuing to engage him. On September 21, 2017, we entered into a confidential settlementdate of this matter withQuarterly Report on Form 10-Q, the plaintiff, which didCompany is not aware of any legal proceedings that could have a material adverse effectimpact on our financial condition/results of operations or cash flows.the Company’s finances.

 

Winn-Dixie Stores, Inc., BI-LO, LLC and Sampson Merger Sub, LLC v. Twinlab Corporation, Case No.: 16-2017-CA-004367, in the Circuit Court of the Fourth Judicial District in and for Duval County, Florida, filed on July 11, 2017. The plaintiffs in this matter allege Twinlab Corporation is in breach of a contract agreement related to unpaid invoices. On September 25, 2017, we entered into a confidential settlement of this matter with the plaintiffs, which did not have a material adverse effect on our financial condition/results of operations or cash flows.

Item 1A.Risk Factors.

 

Risks and uncertainties that, if they were to occur, could materially adversely affect our business or cause our actual results to differ materially from the results contemplated by the forward-looking statements contained in this report and other public statements were set forth in the “Item 1A Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 31, 2017.May 29, 2020.

 

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial conditions and/or operating cash flow.results.

 


Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

As of September 30, 2020, we were in default for lack of compliance with the EBITDA-related financial covenant of the debt agreement with MidCap. The amount due to MidCap for this revolving credit line is $5,084 as of September 30, 2020.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

 

Item 6.Exhibits.The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.

 

Exhibit

Number

Exhibit Description

10.223

Settlement and Release Agreement, dated March 9, 2020, by and between Twinlab Consolidated Holdings, Inc. and Anthony Zolezzi.

  

10.110.224

SecuredSettlement and Release Agreement, dated March 13, 2020, by and between Twinlab Consolidated Holdings, Inc. and 2014 Huntington Holdings, LLC.

10.225

Unsecured Promissory Note, dated August 30, 2017,February 21, 2020, issued by Twinlab Consolidated Holdings, Inc. in favor of Golisano Holdings LLC.

29

10.226

Unsecured Promissory Note, dated February 21, 2020, issued by Twinlab Consolidated Holdings, Inc. in favor of Great Harbor Capital, LLC.

10.227

Fifth Amendment to Subordination Agreement, dated February 21, 2020, by and between Golisano Holdings LLC and Midcap Funding IV Trust.

10.228

Third Amendment to Subordination Agreement, dated February 21, 2020, by and between Great Harbor Capital, LLC and Midcap Funding IV Trust.

10.229

Fourth Amendment to Subordination Agreement, dated February 21, 2020, by and between Great Harbor Capital, LLC, Twinlab Consolidated Holdings, Inc., Twinlab ConsolidationConsolidated Corporation, Twinlab Holdings, Inc., ISI Brands Inc., Twinlab Corporation, Nutrascience Labs, Inc., and Nutrascience Labs IP Corporation, Organic Holdings LLC, Reserve Life Organics, LLC, Resvitale, LLC, Re-Body, LLC, Innovitamin Organics, LLC, Organics Management LLC, Cocoawell, LLC, Fembody, LLC, Reserve Life Nutrition, LLC, Innovita Specialty Distribution LLC, and Joie Essance, LLC in favor of Great Harbor Capital, LLC (incorporated by reference from Exhibit 10.171 to the Form 8-K filed with the Securities and Exchange Commission on September 6, 2017).

10.2

Warrant, dated August 30, 2017, by and between Twinlab Consolidated Holdings, Inc. and Great Harbor Capital, LLC (incorporated by reference from Exhibit 10.172 to the Form 8-K filed with the Securities and Exchange Commission on September 6, 2017).

10.3

Amendment No. 13 to Credit and Security Agreement and Limited Consent, dated as of August 30, 2017, by and among Twinlab Consolidated Holdings, Inc., Twinlab Consolidation Corporation, Twinlab Holdings, Inc., ISI Brands Inc., Twinlab Corporation, NutraScience Labs, Inc., NutraScience Labs IP Corporation, Organic Holdings LLC, Reserve Life Organics, LLC, Resvitale, LLC, Re-Body, LLC, Innovitamin Organics, LLC, Organics Management LLC, Cocoawell, LLC, Fembody, LLC, Reserve Life Nutrition, L.L.C., Innovita Specialty Distribution, LLC, and Joie Essance, LLC, and MidCap Funding X Trust (incorporatedGolisano Holdings LLC, as successor by reference from Exhibit 10.173assignment to the Form 8-K filed with the SecuritiesPenta Mezzanine SBIC Fund I, L.P.

10.230

Fourth Amendment to Subordination Agreement, dated February 21, 2020, by and Exchange Commission on September 6, 2017).between Great Harbor Capital, LLC, Twinlab Consolidated Holdings, Inc., Twinlab Consolidated Corporation, Twinlab Holdings, Inc., ISI Brands Inc., Twinlab Corporation, Nutrascience Labs, Inc. and Nutrascience Labs IP Corporation, Organic Holdings LLC, Reserve Life Organics, LLC, Resvitale, LLC, Re-Body, LLC, Innovitamin Organics, LLC, Organics Management LLC, Cocoawell, LLC, Fembody, LLC, Reserve Life Nutrition, L.L.C., Innovita Specialty Distribution, LLC, and Joie Essance, LLC, and Golisano Holdings LLC, as successor by assignment to JL-Mezz Utah, LLC.

31.1

Rule 13a-14(a)/15d-14(a) Certification.

31.2

Rule 13a-14(a)/15d-14(a) Certification.

32.1

Certification Pursuant to 18 U.S.C. Section 1350.

32.2

Certification Pursuant to 18 U.S.C. Section 1350.

101.INS

XBRL InstanceInstance.

101.SCH

XBRL Taxonomy Extension Schema.

101.CA

XBRL Taxonomy Extension Calculation.

101.DEF

XBRL Taxonomy Extension Definition.

101.LAB

XBRL Taxonomy Extension Label.

101.PRE

XBRL Taxonomy Extension Presentation.

 


 

SIGNATURES

SIGNATURES

 

Pursuant to the requirements of the SecuritiesSecurities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

TWINLAB CONSOLIDATED HOLDINGS, INC.

Date: November 14, 201716, 2020

By:

/s/ Naomi L. WhittelDaniel DiPofi

Naomi L. Whittel

Daniel DiPofi

Chief Executive Officer

Date: November 14, 201716, 2020

By:

/s/ Alan S. GeverKyle Casey

Alan S. Gever

Kyle Casey

Chief Financial Officer and Chief Operating Officer

 

31

30